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Abstract
Background and Methods
Following renal transplantation there is excellent 1-year graft survival but thereafter
a steady rate of graft loss that is due mainly to premature patient death or cumulative
graft injury as occurs in chronic allograft nephropathy (CAN). CAN is a clinico-
pathological term that applies to renal transplants when there is a decline in function
in association with fibrointimal hyperplasia of blood vessels and progressive scarring
of the graft interstitium. There are both immunological and non-immunological
aetiologies of CAN. Renal transplant recipients with allograft failure secondary to
CAN account for roughly 3% of all entrants to chronic dialysis programmes in the
UK (approximately 150 per annum), increasing the demand placed on this limited
resource. Allograft failure also has a considerable impact on patients awaiting call-up
for transplantation, for example as many as 1 in every 6 patients transplanted in the
UK in the year 2000 had previously received a renal transplant. The number of
patients listed for renal transplantation in the UK has increased by more than 50%
since 1990 and currently exceeds 6,000. The clinical management of renal transplant
recipients (RTRs) should therefore include anticipation, prevention, early detection
and optimal treatment of CAN. The component studies of my thesis have addressed
specific areas within each of these main divisions. They can be summarised as
follows: screening tests for potential RTRs that may establish a predisposition to the
development of CAN within their allograft (genetic profiling for Transforming
Growth Factor-beta 1 (TGF-beta 1), a cytokine that promotes arteriosclerosis and
14
fibrosis, and lymphocyte sensitivity to the immunomodulatory effects ofCsA in vitro
using a mitogenic stimulus); measurement of the degree and variability of CsA
exposure (based on C2 and CO values); evaluation of candidate urine markers for
incipient CAN (TGF-beta 1 and the lysosomal enzyme NAG); validitation of
alternative measurements ofrenal transplantfunction that are more sensitive to small
reductions in glomerular filtration rate (serum cystatin C and creatinine-based GFR
formulae); and finally a prospective, randomised controlled study of
immunusuppression conversion for patients with established CAN (MMF and
reduced dose CsA vs tacrolimus for CsA vs 'no change' controls).
Results and discussion
The notion of a screening programme for potential RTRs to reduce the prevalence of
CAN through identification of those 'at risk' is a credible one. However, the
inclusion in such a programme of genetic profiling to predict post-transplant TGF-
beta 1 expression and measurement of lymphocyte sensitivity to CsA in vitro is not
supported by the study data. Modified studies that examine larger populations and
combinations of screening tests may be contemplated in the future. Control groups
need to be rigorously defined, for example by inclusion of histopathological criteria.
It would also appear that the measurement of candidate urine markers for incipient
CAN (TGF-beta 1 and the lysosomal enzyme NAG) is of little predictive or
diagnostic value. Proteomic analyses may help to identify a family of discriminatory
urine markers for inclusion in future non-invasive graft surveillance programmes.
The studies relating to measurement of serum cystatin C (a more sensitive marker of
small reductions in GFR than serum creatinine) and calculation of GFR using the
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Levey (MDRD) prediction formula indicate that both are useful in the detection
and/or quantification of early renal allograft dysfunction. A greater awareness of
diminishing renal clearance would increase the opportunity for effective therapeutic
intervention.
The studies of blood CsA monitoring indicate that a more accurate quantification of
CsA exposure may be important in reducing both the incidence of acute transplant
rejection during the immediate post-transplant period (a well documented risk factor
for the development of CAN) and the rate of chronic disease progression in
established CAN. A large intra-individual variation in CsA exposure may indicate
poor adherence to treatment regimens rather than variation in drug bioavailability.
In the study of immunosuppression conversion for RTRs with established CAN, a
comparison of reciprocal of creatinine vs time (ROCT) slopes before (-12/12 - 0) and
after (0 - 6/12) intervention revealed a treatment advantage for patients whose
immunosuppression was changed to MMF/ reduced dose CsA (p < 0.05). Similar
results were obtained in the GFR analysis. Exclusion of patients with an initial GFR
< 20 ml/min/1.73m2 from the analysis gave a result that was statistically and
clinically more striking (n = 27, p < 0.05), indicating that immunosuppression
conversion should be considered at an early stage in the development of CAN. A
comparison of pre-study and 3/12 - 12/12 ROCT slopes (to isolate the early effect of
CsA dose reduction on renal transplant haemodynamics) showed a non-significant
difference between treatment groups (MMF/ reduced dose CsA vs controls, p =
0.08), suggesting that the CsA dose reduction component of the regimen is most
beneficial. The number of study participants was suboptimal, mainly because of slow
recruitment in some of the participating centres. A more extended period of follow-
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up would have provided information about the longer-term safety and effectiveness




There is a major problem of donor organ shortage in the United Kingdom (UK). We
have one of the lowest European donor rates at around 13.5 pmp per annum.
Between 1990 and 1998, there was an 18% reduction in the annual number of
cadaveric renal transplants in the UK and a 50% increase in the number of patients
on the transplant waiting list (Figure 1). This trend has continued up to the present
day. The widening gap between supply and demand inevitably results in a
lengthening of the average waiting time for renal transplantation (UK Transplant
2001). The number of patients on either the 'active' or 'temporarily suspended' UK
renal transplant waiting lists at the end ofDecember 2003 was 6,447, a rise of 2% on
the previous year's total. The situation would be even worse if it were not for a
recent expansion of living donor programmes across the UK. In the year 2003, 439
living donor renal transplants were performed, accounting for just over a quarter of
all UK renal transplant activity.
What can be done to tackle the problem? There are a number of challenges facing the
transplant community. It is essential that the general public is informed about organ
donation, and individuals must be encouraged both to join the Organ Donor Register
and to discuss with family members their wish to be considered as potential organ
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donors in the event of their death. A more dramatic step would be to change from an
'opt in' to an 'opt out' system of organ donation (whereby every person living in the
UK would be deemed to have consented to organ donation unless they had
previously registered their objection to the same). This approach raises a number of
difficult ethical issues and opinion is understandably divided. The recent UK
Potential Donor Audit has shown that approximately 50 % of families approached
about organ donation are prepared to give their consent (UK Transplant 2004). The
report also states that an increase in the number of UK transplant coordinators is
necessary to maximise donation rates from both heart-beating and non-heart beating
donors (especially within the non-white population). These ideas have been brought
together in a blueprint for UK transplant services published by the Department of
Health (Saving Lives, Valuing Donors - A Transplant Framework For England,
Department of Health 2003). Other service priorities include improved HLA
matching of cadaveric renal allografts (new arrangements for organ sharing within
large alliances such as the North of England Transplant Alliance (NETA) have
already made an important difference in this regard) and better characterisation of
recipient anti-HLA antibodies. The latter will reduce the likelihood of an unexpected
positive crossmatch test and therefore improve the efficiency of organ allocation.
There is also interest in developing more effective organ preservation solutions that
will reduce cold injury and the occurrence of delayed graft function.
The incidence of acute renal transplant rejection is much lower than in the past for a
number of reasons, but the absence of a proportionate improvement in long-term
transplant survival raises two other important challenges, namely a reduction in
patient mortality (prevention of premature cardiovascular disease will be the key
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aim) and graft loss resulting from chronic allograft nephropathy (CAN). Renal
transplant recipients with allograft failure secondary to CAN account for roughly 3%
of all entrants to chronic dialysis programmes in the UK (approximately 150 per
annum), increasing the demand placed on this limited resource. Allograft failure also
has a considerable impact on patients awaiting call-up for transplantation, for
example as many as 1 in every 6 patients transplanted in the UK in the year 2000 had
previously received a renal transplant.
In this thesis I have considered a number of approaches to the specific challenge of
minimising the negative impact ofCAN on renal transplant survival. The studies are
wide-ranging and can be placed into three main categories (other well-established
approaches are included in italics):
(1) Anticipation/ prevention of CAN - identification of predisposing factors
• Organ quality (donorfactors, procurement andpreservation factors)
• HLA match
• Cytokine genotype
• In vitro cyclosporin (CsA) sensitivity
• CsA exposure
- C2 (the 2 hours post-dose blood CsA level) monitoring and the prevention of
early acute transplant rejection (AR)
- intraindividual variability ofCsA exposure (CvarCO)
(2) Early non-invasive methods of detecting CAN
• Urine markers - TGF-beta (Transforming Growth Factor beta) / N-acetyl P-D
glucosaminidase (NAG)
• Serum cystatin C
• GFR (glomerular filtration rate) prediction formulae
(3) Treatment of CAN
• Blood pressure control/ lipid-lowering therapyZ ACE (angiotensin converting
enzyme) inhibitor therapy
• Randomised controlled trial of mycophenolate mofetil (MMF) and CsA dose
reduction/ tacrolimus in place of CsA/ 'no change' standard dose CsA for
patients with established CAN
The concepts underlying these studies are outlined in the opening sections of the
relevant chapters. The final chapter contains a general summary of the study findings
and future strategies that may help to prevent, identify and treat CAN.
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End-stage renal failure (ESRF) - aetiology,
incidence, morbidity and mortality
2.1 Aetiology of ESRF
Progression to end-stage renal failure (ESRF) occurs in a large proportion of patients
with chronic renal disorders. Diabetes mellitus and hypertension are the most
common causes of ESRF in the United Kingdom (UK) followed by the various
glomerulonephritides. Stability of renal function may be achieved in patients with
hypertensive nephrosclerosis and obstructive uropathy, where the precipitating factor
can be controlled to some extent by appropriate therapy. Progression to ESRF tends
to occur more rapidly in chronic glomerular disease and diabetic nephropathy than in
autosomal dominant polycystic kidney disease (ADPKD) and chronic
tubulointerstitial disease. The rate of disease progression correlates positively with
the degree ofproteinuria (Williams et al 1988).
It is understood that the mechanism of progressive renal injury ('scarring') is
common to nephropathies of diverse aetiologies and is influenced by genetic,
haemodynamic, metabolic and dietary factors. The relevance of such factors to the
pathogenesis of chronic allograft nephropathy (previously termed chronic transplant
rejection) will be discussed in a later section. Control of blood pressure and
moderation of dietary protein and saturated fat intake may slow the rate of disease
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progression, irrespective of the underlying renal pathology (Levey et al 1996, El
Nahas 1998).
2.2 Incidence of ESRF
The incidence of ESRF in different parts of the world varies with population
demographics and the quality of local health care provision. The UK Renal Registry
Report summarises data from more than 30 renal units in England, Scotland and
Wales (Ansell et al 1999). In 1998, 92.2 new patients per million population (pmp)
per year required renal replacement therapy, and the point prevalence of adult
patients receiving renal replacement therapy in the whole of the UK was estimated to
be 31,316 (more than 500 pmp). One year later, the number had increased by
approximately 4.3%. This trend is likely to continue well into the future.
Approximately 50% of prevalent patients are on haemodialysis (HD) or peritoneal
dialysis (PD) and the remainder have a functioning renal transplant.
The most comprehensive epidemiological data for dialysis populations are provided
by the United States Renal Data System (USRDS, University of Michigan). It is
apparent that the number of patients receiving maintenance dialysis in the United
States is increasing at a net rate ofmore than 10% per annum and currently exceeds
300,000 (more than 600 pmp). Similar rates of increase have been reported in Europe
and parts of the UK (Berthoux et al 1999; Ansell et al 1999). In comparison with
historical dialysis populations, new patients are generally older and more likely to be
diabetic and/or have significant comorbidity (for example atherosclerotic coronary
artery disease, cerebrovascular disease, peripheral vascular disease, chronic
obstructive pulmonary disease or cancer).
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2.3 Morbidity and mortality of patients with ESRF receiving renal
replacement therapy
Dialysis treatment can offer good quality rehabilitation to patients with ESRF, but
overall there is premature mortality. Risk factors for the development of
atherosclerotic coronary artery disease (such as anaemia, hypertension and
hypercholesterolaemia) are prevalent in pre-dialysis populations and are not
influenced significantly by renal replacement therapy in the form ofHD or PD.
The death rate from ESRF in the European Union (EU) during 1996 was 69 pmp per
annum. The death rate in non-diabetic patients aged 45 to 54 years with ESRF was 5
to 10 times higher than in matched cohorts of the general population (Brunner et al
1992). The annual mortality rate (number of deaths/ patient years at risk of death x
100) for ESRF patients on dialysis in the USA in 1997 was 20% (USRDS Annual
Data Report 1998). The corresponding figure for UK patients was 26.3% (Renal
Registry data). The apparent difference in mortality between the two countries may
be explained by differences in methods of calculation (deaths that occur within the
first 90 days of commencing chronic dialysis therapy are discounted in USRDS
analyses). Cardiovascular disease is the most common cause of death for ESRF
patients, followed in frequency by infection (Valderrabano et al 1993).
Death from cardiovascular disease occurs in renal transplant recipients at
approximately half the overall rate for renal failure patients. The difference is due in
part to selection of only the fittest patients for transplant listing (Briggs et al 1998).
Patient and graft survival rates are discussed in Chapter 3. The broad picture is one
of excellent one-year graft survival but thereafter a steady rate of graft loss that is
consequent upon either premature patient death (patient survival at 5 years after renal
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transplantation is 85-90%) or cumulative graft injury (such as occurs in chronic
allograft nephropathy). It is argued by some that patient death is an acceptable form
of graft loss in that the transplant has successfully provided life-long renal
replacement. The key issue is whether or not patients should be screened thoroughly
prior to transplantation and then excluded from transplant listing if their overall
prognosis is poor, thereby making more efficient use of a limited resource. Decisions
to exclude patients in this manner are of course complex and controversial and there
are likely to be inconsistencies of approach between and within renal units.
Turning briefly to quality of life issues, subjective quality of life estimations and
employment rates are significantly higher for renal transplant recipients (especially
those who receive a kidney from a living donor) than for patients who remain on
chronic dialysis treatment. This reflects the clear superiority of transplantation in
terms of renal clearance and consequently the removal of restrictions on diet, fluid
intake, working patterns, travel and so forth. There are particular benefits of
transplantation in terms of improvement in anaemia, peripheral and autonomic
neuropathy and sexual function.
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Patient and graft survival following renal
transplantation
Patient death accounts for between 22% and 48% of renal allograft loss after the first
post-transplant year depending on the age and comorbidity of the recipient
population (Bia 1995). The incidence of myocardial infarction and cerebrovascular
events may be 25-fold higher than in the general population (Meyer et al 1996,
Kasiske et al 2001). Atherosclerotic deaths account for up to 55% of all late
transplant deaths in some series (Meyer et al 1996). Infection and malignancy are
more common in immunosuppressed patients and account for approximately a third
of late deaths. Less common causes of death include hepatobiliary disease and
suicide. The incidence of suicide is 1% in some series, which is 50 times higher than
the corresponding figure for age-matched controls.
Short-term graft survival in the UK has increased steadily in recent years due in part
to more effective immunosuppressive therapy. The one-year survival rate for first
cadaveric transplants performed in 1997 and 1998 (defining graft loss as a return to
chronic haemodialysis or death of the recipient) was 86% (UK Transplant 2001). In
the USA, the monthly rate of cadaveric renal allograft loss during the first 3 months
post-transplant fell from 9.7% to 3.8% between 1983 and 1992 (USRDS Annual
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Report 1995). The attrition rate in subsequent months was also reduced, from 1.8%
to 0.6% for the 4-12 months post-transplant period, and from 1.0% to 0.5% during
the second post-transplant year. The projected half-life of primary cadaveric grafts
(the estimated number of post-transplant years at which only one half of first
transplants will be functional) transplanted in 1995-96 is 100 months. This statistic
compares favourably with a projected half-life of 80 months for grafts transplanted in
the early 1990s. Hariharan et al recently concluded that improvements in graft half-
life are related to conservation of renal function in the first year post-transplantation
(Hariharan et al 2002). The graft half-life estimates for living donor grafts
transplanted in 1990-91 and 1995-96 are 130 months and 175 months respectively.
However there is some cause for concern. According to USRDS data, there was no
change in the monthly rate of cadaveric allograft loss after the second post-transplant
year (0.7% versus 0.8%) between 1983 and 1988. Similarly, the 5-year graft survival
rate in the UK has remained disappointingly low at around 65%. It is likely that both
immunological and non-immunological factors determine graft outcome. These are
discussed in Section 4.1.
Renal transplants fail for many reasons (Thiru 2001). A small number fail
immediately after transplantation for technical reasons. The rare complication of
arterial and/or venous thrombosis of the graft occurs typically within the first 2-3
days post-transplant but may occur much later as a complication of an acute rejection
episode. Problems relating to the arterial anastamosis are more likely if the donor
kidney is supplied by more than one renal artery. Thrombosis is heralded by a sudden
cessation of urine output and, in the case of venous occlusion, by graft swelling and
localised pain. The majority of grafts in which arterial or venous thrombosis occurs
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have irrevocable loss of function. Early ureteric complications include urinary leak
following anastomotic breakdown and obstruction resulting from kinking, stenosis or
stent blockage.
Early graft loss as a consequence of accelerated rejection is an extremely rare event.
It is triggered by the action of pre-formed recipient cytotoxic antibodies that are
directed against either human leucocyte antigens (HLAs, see Section 4.1) or ABO
blood group antigens expressed by the donor. It occurs immediately post¬
transplantation {hyperacute rejection) although delayed hyperacute rejection
occurring several days after engraftment is also recognised. Cytotoxic alloantibodies
bind to the endothelial surfaces of graft arterioles and activate complement, leading
to severe vascular injury with arteriolar occlusion and thrombosis. Patients are
usually oligoanuric and have a fever and graft tenderness. It is often necessary to
perform a transplant nephrectomy. A pre-transplant crossmatch test (incubation of
donor lymphocytes with recipient serum in the presence of complement, allowing
detection of donor-specific cytotoxic antibody) is performed routinely to reduce the
incidence of adverse clinical outcomes resulting from such donor-recipient
incompatibility.
Acute rejection may also result in graft loss. Cell-mediated acute rejection is the
most common form of acute rejection. Donor antigens, particularly HLA antigens,
are recognised by specific T cells that induce either direct cytotoxicity or a delayed
hypersensitivity response. The major histopathological feature is a widespread
infiltration of the renal interstitium by leucocytes, most ofwhich are mature T cells.
Lymphocytes and monocytes also extend into the walls and lumina of renal tubules
('tubulitis') and the vascular endothelium. Antibody-mediated acute rejection is less
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common and is characterised primarily by necrotising arteritis with fibrinoid necrosis
and a neutrophilic infiltrate. Endothelial cells are severely damaged or absent and
luminal thrombosis is common. There may be infarction of the renal cortex with
interstitial haemorrhage. Immunofluorescence studies typically reveal deposition of
IgG and C3 in the walls of arteries. The introduction of more potent
immunosuppressive agents and improvements in tissue typing in recent years has
reduced greatly the risk of catastrophic acute cellular or vascular rejection.
Chronic renal allograft dysfunction (CRAD) may result from a variety of processes
but is often secondary to chronic allograft nephropathy (CAN, see below).
Estimation of the true prevalence of CAN would require regular 'protocol' biopsies
of all transplant recipients even when graft dysfunction is not evident, a policy that is
adopted in only a few centres. Solez et al found histopathological evidence of CAN
at 2 years post-transplant in approximately two-thirds of cadaveric renal transplants
receiving calcineurin-inhibitor immunosuppression (Solez et al 1998). Serum
creatinine is used as a marker of glomerular filtration rate (GFR) in clinical practice
but it is insensitive to changes in renal function when the GFR is more than
75ml/min/1.73m (Stewart Cameron el al 1998). There is a hyperbolic relationship
between GFR and serum creatinine, such that GFR values in excess of
75ml/min/1.73m2 are represented on a relatively flat portion of the 'serum creatinine
vs GFR' curve and any decrease in GFR will produce only a small increase in serum
creatinine. Conversely, a decrease in GFR for patients with pre-existing renal
impairment (for example a GFR of less than 30ml/min/1.73m2) is associated with a
relatively large increase in serum creatinine (i.e. serum creatinine is a more sensitive
marker of change in renal function within this GFR range). Another source of
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difficulty in estimating the prevalence of CAN is differentiating between the
histopathological features of CAN and those of other processes such as ischaemic
nephropathy and cyclosporin (CsA) toxicity. This is discussed in more detail in
Section 4.5.
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Chronic allograft nephropathy (CAN)
Chronic allograft nephropathy (CAN) is a poorly characterised clinico-pathological
term that applies to renal transplants when there is a slow and often variable rate of
decline in function with fibrointimal hyperplasia of blood vessels, glomerular
changes and progressive scarring of the graft interstitium. Urinary protein excretion
exceeds 0.5 g/day in approximately a quarter of cases (Massy et al 1996). A
diagnosis of CAN requires exclusion of other causes of graft dysfunction such as
hypoperfusion, urinary tract obstruction, recurrence of original renal disease, allergic
interstitial nephritis, viral infection (cytomegalovirus and BK polyoma virus),
hypertensive nephropathy and drug nephrotoxicity (including the calcineurin
inhibitors cyclosporin (CsA) and tacrolimus (FK506)), although a multifactorial
aetiology is seen in many patients. Investigation may include an ultrasound scan of
the transplant, estimation of renal blood flow using colour-flow Doppler and a
transplant biopsy.
CAN is the most frequent cause of late allograft failure excepting death with a
functioning transplant. United Network for Organ Sharing (UNOS) Scientific Renal
Transplant Registry data for a cohort of de novo cadaveric renal allograft recipients
transplanted in 1994-95 have shown that 9% of graft loss in the first year resulted
from chronic rejection, 24% from acute rejection and 28% from death with a
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functioning transplant. In the second post-transplant year, 34% of graft loss was
attributed to chronic rejection, 6% to acute rejection, and 38% to patient death
(Cecka 1996). It has been estimated that as many as 40% of patients with normal or
near-normal transplant function will have mild histological features of CAN on
biopsy (Mahony et al 1987; Dennis et al 1989; Insoniemi et al 1992). Progression to
ESRF may occur in a few months or over a period of several years (Kasiske et al
1991).
UK transplant recipients with allograft failure secondary to CAN account for roughly
3% of all entrants to chronic dialysis programmes (approximately 150 per annum),
increasing the demand placed on this limited resource. Allograft failure also has a
considerable impact on patients awaiting call-up for transplantation, for example as
many as 1 in every 6 patients transplanted in the UK in the year 2000 had previously
received a renal transplant.
Renal transplantation is of course the most cost-effective way of managing patients
with ESRF (United States Renal Data System Annual Report 1993). The cost per
annum for a patient receiving dialysis treatment in the UK in 1992 was calculated to
be £21,000, compared to £4,000 per annum for a renal transplant recipient (Mallick
1997). The annual net cost to the NHS for treating patients who return to dialysis
because of graft failure is therefore likely to be in the order of hundreds of thousands
of pounds (Morris-Stiff et al 1998a).
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4.1 Aetiology of CAN
It is probable that there are multiple aetiologies of CAN, both immunological (HLA
mismatch (Kupin et al 1997), frequency and severity of acute rejection episodes
(Van Saase et al 1995; Matas et al 1994), CsA dose (Almond et al 1993)) and non-
immunological (warm and cold ischaemia time (Shoskes et al 1998; Yilmaz et al
1993), donor age (Terasaki et al 1992), size mismatch of donor and recipient (Kupin
et al 1997), hypertension (Opelz et al 1998), hypercholesterolemia (Brazy et al
1992), viral infection (Lemstrom et al 1994)), that link into a final common pathway
of fibrosis or scarring. A change in the nomenclature from chronic rejection
(implying a purely immunological aetiology) to CAN lends greater emphasis to this
concept.
Immunological factors
The slower rate of chronic transplant loss in well-matched recipients compared to
poorly-matched recipients may be taken as a measure of the contribution of
immunological factors to the development of CAN, although there are studies in
which a survival advantage has not been demonstrated (Kerman et al 1993;
Reinsmoen 2000). The latter may be related to a narrow distribution of human
leucocyte antigen (HLA, see below) matching within some transplant populations,
making it more difficult to demonstrate a beneficial effect of matching on outcome.
It may be also that there are more appropriate ways of assessing histocompatibility
than HLA match. For example, one recent study demonstrated that the number of
cross-reactive epitope group (CREG) matches, but not the number of HLA
mismatches, predicted long-term graft survival (Sijpkens et al 1999). The CREG
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system represents a broader grouping ofHLA epitopes (amino acid sequences within
antigen binding sites) that are shared among different HLA specificities. Data from
the Collaborative Transplant Study and our own population of renal transplant
recipients suggest that CREG matching is of little benefit in terms of long-term
transplant function (Wujciak et al 1999, Clark et al 2002). The average half-life of
cadaveric grafts where there is a complete donor-recipient mismatch at the HLA A,
B and DR loci has been estimated to be 7.4 years, compared to a half-life of 16.5
years for grafts that are perfectly matched at these loci (Terasaki et al 1990). In the
UK there have been significant improvements in HLA matching following a revision
of the rules governing the National Kidney Allocation Scheme.
MHC (major histocompatibility complex) antigens play a central role in the immune
response to transplanted foreign tissue. The genetic code for these antigens is similar
in all mammalian species. Characterisation of the human MHC (also referred to as
the HLA system) has improved following the advent ofDNA typing methods. MHC
class I antigens (a composite group incorporating HLA categories A, B and C) are
expressed on the surface of most nucleated cells and are responsible for the
presentation of foreign antigen to CD8-positive T cells. T cells can be divided into
two major subpopulations on the basis of their cell membrane glycoproteins (CD8
and CD4). It is thought that CD8 and CD4 are receptors for MHC class I and class II
antigens respectively. MHC class II antigens (HLA category D) are expressed mainly
on resting B cells, macrophages and some endothelial cells, although the cytokine
tumour necrosis factor alpha (TNF-a) may induce expression on other cell types (e.g.
renal tubular cells and T cells) during an episode of inflammation. The MHC
demonstrates a remarkable degree of genetic polymorphism. Even within national
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transplant organisations managing large pools of donors and recipients, avoidance of
donor-recipient mismatch at the HLA A, B and DR loci (classified by serological
typing methods) is achieved in only 10% of cases. The existence of'permissible' and
'taboo' mismatches suggests that, in addition to 'public' determinants for given HLA
specificities, there are 'private' determinants (amino acid sequences) that may or
may not be homologous with the 'private' determinants of other HLA specificities
(Dupont et al 1997). MHC incompatibility (particularly MHC class II) is the prime
cause ofacute allograft rejection (Basadonna et al 1993).
HLA-specific anti-lymphocyte antibodies are present in a large proportion of patients
awaiting renal transplantation, mostly as a result of exposure to non-inherited
maternal antigens (NIMAs) in utero, pregnancy, transfusion of blood products and
previous engraftment. The degree ofHLA sensitisation for an individual is expressed
as %PRA ('panel reactive antibodies'). In simple terms, %PRA may be defined as
the proportion of panel lymphocytes (taken from a random sample of individuals and
therefore representative of the distribution of donor HLA phenotypes within the
general population) that react to antibodies in patient serum. A minority of patients
(10 - 20%) are 'highly sensitised', that is one or more of their stored serum samples
(collected at regular intervals prior to transplantation) reacts with 80% or more of the
panel lymphocytes (>80% PRA). According to data from the United Network of
Organ Sharing (UNOS) Scientific Registry, recipients of a first cadaveric transplant
with a PRA of more than 50% have a 6% lower graft survival at one year as
compared to recipients with a PRA of less than 10% (Cecka 1996).
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Non-immunological factors
It is likely that non-immunological factors also contribute significantly to the
progression of CAN. An analysis of pooled UNOS data has shown that the survival
of kidneys from living-unrelated and one-haplotype match living-related donors (i.e.
one half of the HLA genes of the donor and recipient are identical) is extremely good
and much superior to the survival of kidneys from a cadaveric source with similar
degrees ofHLA match. This suggests that the condition of the kidney at the time of
transplantation is an important, alloantigen-independent predictor of CAN (Terasaki
et al 1995). Organs from cadaveric donors in their late 50s and 60s may have age-
related impairment of function, particularly when the cause of death is vascular
rather than traumatic. Older kidneys may also be more susceptible to acute tubular
necrosis. CAN is more likely to develop in kidneys from donors who are female,
black and either older than 60 years old or less than 3 years old (Chertow et al 1996).
'Nephron dose' may be the explanation for this observation, as discussed later in this
section. It is relevant to note that the mean age of cadaveric kidney donors in the UK
has increased steadily from 37 years to 43 years over the past decade (UK Transplant
2001).
Retransplantation experiments in animals have demonstrated the importance of
alloantigen-dependent events in the development of chronic graft deterioration but
they suggest also that a 'point of no return' exists, before which acute rejection or
early chronic rejection can be reversed and beyond which the process of fibrosis
becomes independent of the stimulus and progresses inexorably (Yang et al 1995;
Tullius et al 1997; Tullius et al 1998). Yang et al studied the in situ expression of
platelet-derived growth factor (PDGF-beta), a cytokine that is produced in response
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to wound injury. Rat allografts (Fischer 344 to Lewis) were retransplanted into
syngeneic Fischer recipients at 12 weeks (once CAN had developed) and evaluated
for glomerular PDGF-beta mRNA expression after a further 12 weeks. Expression
was significantly higher in allografts (Fischer to Lewis) as compared to isografts
(Lewis to Lewis), but the difference was less marked in retransplants (Fischer to
Lewis and then back to Fischer), providing evidence of the importance of
alloantigen-dependent factors in the progression ofCAN. Tullius et al retransplanted
acutely rejecting rat kidney grafts (Lewis to BNF1) into syngeneic (Lewis)
recipients. For the allografts with massive cellular infiltrates and necrosis, rejection
could not be reversed by retransplantation and the syngeneic recipients later died of
renal failure. In contrast, for allografts that were less severely damaged by rejection a
complete reversal of the rejection process occurred following retransplantation and
this was accompanied by a significant fall in urinary protein excretion.
The inexorable decline in function following retransplantation of the more severely
damaged rat allografts is not fully explained. One theory relates to adaptive changes
in renal haemodynamics (Brenner et al 1992). A critical reduction in the number of
functioning nephrons may produce hypertrophy of residual nephrons secondary to
increased intravascular pressure and flow. This process is termed glomerular
hyperfiltration (Gottschalk 1971) and it would of course be exacerbated in the
presence of systemic hypertension. The permselectivity of the glomerular basement
membrane (GBM) is reduced, so leading to an increase in urinary protein excretion.
Accumulation of protein deposits within the mesangium stimulates mesangial cell
proliferation and deposition of matrix with subsequent glomerulosclerosis (Couser et
al 1975). The associated loss of glomerular function exerts a positive feedback
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stimulus that produces compensatory hyperfiltration in less affected glomeruli,
contributing in turn to further glomerular injury and destruction. Hyperfiltration
injury has been reported in a number of experimental and clinical models in which
there is nephron loss (Brenner et al 1982). One way of estimating its importance in
the transplant setting is to examine the effect of donor-recipient size mismatching on
graft survival. Published studies have given conflicting results (Miles et al 1996; Lee
et al 1997; Kim et al 2001). The glomerular pathology that is associated with
hyperfiltration, namely focal glomerular sclerosis, is not prominent in chronically
rejecting renal allografts, suggesting that hyperfiltration does not in fact play a major
role in the development of CAN. CsA promotes vasoconstriction of the afferent
glomerular arteriole and may therefore protect functioning nephrons from
hyperfiltration injury at the expense of glomerular ischaemia. Focal glomerular
sclerosis was not a frequently reported histopathological finding in the pre-CsA era,
perhaps contradicting this hypothesis.
Hyperlipidaemia may contribute to the development of CAN. Foam cells and
apolipoprotein deposits are seen commonly in the vascular lesions of chronic
rejection. Prospective and retrospective studies have documented an association
between CAN and raised serum levels of cholesterol and/or triglycerides (Guijarro et
al 1995; Fernandez-Miranda et al 1997; Roodnat et al 2000). Randomised trials in
human cardiac allograft recipients have shown that 3-hydroxy-3-methylglutaryl-
coenzymeA (HMGCoA) reductase inhibitors may be effective in limiting cardiac
allograft vasculopathy (Kobashigawa et al 1995). These are discussed in more detail
in Section 4.6.6.
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The expression of MHC class II antigens in renal allografts has been shown to
increase during CMV infection (Lemstrom el al 1994; von Willebrand et al 1986).
The relationship between CMV infection and long-term graft survival may be causal
or simply an epiphenomenon resulting from the dual association of CMV infection
with acute rejection (which typically precedes infection) and increased donor age,
both of which are considered to be independent predictors of poor long-term graft
survival (Cecka 1997).
Brain death and organ reperfusion (the flow of recipient blood through a
transplanted organ that has been preserved at low temperature following its removal
from the donor) are associated with an increase in both MHC class II expression and
cytokine production. Importantly, these stimuli are of course avoided in living donor
transplantation. The duration of cold injury to cadaveric grafts in the UK approaches
24 hours on average. Immunological upregulation may be caused by the dramatic
catecholamine release that accompanies brain death and the ischaemic and oxidative
injury that is associated with organ reperfusion (Pratschke et al 1999).
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4.2 Histopathology of CAN
The histopathological features of CAN are generally non-specific. Vascular changes
include concentric intimal thickening of arteries and arterioles with infiltration of
macrophages and lymphocytes and migration of myofibroblasts from the tunica
media. Multilayering of peri-tubular capillaries may also be seen. Glomerulopathy
comprises wrinkling and collapse of the glomerular tuft, mesangial matrix expansion
and hypertrophy of remnant glomeruli. Tubular atrophy and interstitial fibrosis are
prominent features, the latter resulting from deposition of extracellular matrix
proteins such as collagen type IV and laminin. Immunofluorescence studies
commonly reveal linear fibrin and granular IgM, Clq and C3 deposits along capillary
walls.
The Banff classification represents an organised and consistent approach to the
classification and grading of the various structural lesions that occur in renal
allografts, as agreed by an international committee of specialists (Racusen et al
1999). The severity of the histopathological features is considered within the Banff
international classification system for CAN (category V, grades 1-3), added
weighting being given to tubulo-interstitial changes as these are ofgreater prognostic
significance and interpretation is less prone to sampling error. The histopathological
features of chronic rejection in other solid organ transplants are similar to those of
CAN, in that there is obliterative fibrosis of hollow structures within the graft, be
they blood vessels, bronchioles, bile ducts or pancreatic ducts.
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4.3 Pathophysiology of CAN
There are several theories concerning the pathophysiology ofCAN. Essentially, renal
injury of any kind promotes an immunological response with influx of inflammatory
cells, release of chemical mediators (such as cytokines, enzymes and growth factors),
proliferation of tissue fibroblasts and deposition of extracellular matrix proteins that
results in scarring. The strength of this response is influenced by genetic factors
(Section 4.4). A substantial loss of functioning renal mass promotes further renal
damage through the effects of hypertension, proteinuria and dyslipidaemia
(Mackenzie et al 1994; Benediktsson et al 1996). Transplants with a lower initial
nephron mass (e.g. kidneys from paediatric donors, females, blacks and older donors
with age-dependent glomerulosclerosis) are more susceptible to CAN (Chertow et al
1996).
The importance of apoptosis and premature senescence of allograft parenchymal
cells in CAN has not been fully established (Wever et al 1998; Halloran et al 1999).
Apoptosis describes an orderly sequence of events comprising recognition of cells
that are expressing pro-apoptotic cell surface receptors, cessation of metabolic
activity within these cells, disassembly of the cells and disposal of their contents
(Steller 1995). The process applies ordinarily to cell populations with a high turnover
rate (e.g. leucocytes and intestinal epithelial cells) but may also occur in cells that are
the target of sub-threshold chemical or physical insults. Above the threshold, cellular
disruption rather than apoptosis would be more likely to occur, with release of
enzymes and inflammatory mediators that exacerbate cellular injury and lead
ultimately to tissue necrosis. Thus apoptosis is programmed cell death, whereas
necrosis describes unprogrammed destruction of contiguous cells in part of an organ
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or tissue. Inducers of apoptosis include a family of lethal cytokines that activate a
corresponding family of so-called 'death receptors'.
The relevance of thrombophilia (both congenital and acquired) to the development of
CAN is not yet clear (Irish 1999). It is conceivable that the vascular endothelial
damage seen in CAN is more likely to be complicated by thrombotic occlusion of
arterioles in patients who have a coagulopathy, resulting in tissue ischaemia and
more rapid disease progression. Fischereder et al tested 132 consecutive renal
transplant recipients for protein C and S activity, lupus anticoagulant (LA) and the
factor V Leiden (FVL) mutation. A total of 18 patients had a detectable abnormality
(FVL mutation, 10; LA, 6; protein S deficiency, 2). The median graft survival for
patients with thrombophilia was 30 months compared to 86 months for patients
without thrombophilia (p<0.01) (Fischereder et al 1998). A review of 109 renal
transplant recipients performed by Ekberg et al found that the factor V Leiden
mutation was an additional risk factor for early renal graft loss in patients with acute
vascular rejection (Ekberg et al 2000). There is also evidence of an association
between a prothrombin gene mutation and early graft thrombosis, although case
numbers are small (Oh et al 1999).
Recent studies have examined plasma homocysteine (Hcys) levels in renal transplant
recipients. Hyperhomocystinaemia is associated with premature vascular disease.
Plasma levels depend to some extent on the activity of methyltetrahydrofolate
reductase (MTHFR), an enzyme that catalyses the remethylation of Hcys to
methionine. Mutations of the MTHFR gene may result in the synthesis of a more
thermolabile enzyme with reduced catalytic activity. It has been shown in renal
transplant recipients that homozygosity for the C677T MTHFR gene mutation is
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associated with higher homocysteine and lower folate levels in the serum (Fodinger
etal 1999).
Other workers have demonstrated that CsA treatment is associated with increased
platelet aggregation and impaired fibrinolysis (Vanrenterghem et al 1985; Malyszko
etal 1996).
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4.4 The role of cytokines and the importance of cytokine genotype
in CAN
The cytokine family comprises a large and diverse group of low molecular weight,
soluble proteins that regulate the immune response. They bind to cell surface
receptors and can activate or suppress cells within which they are synthesised,
neighbouring cells and distant cells (autocrine, paracrine and endocrine effects
respectively) (Arai et al 1990). Typically, cytokines are produced for only brief
periods, have high affinity for their cell surface receptors and display multiple
synergistic and overlapping effects (pleiotropy). This may explain the poor efficacy
of an immunosuppressive therapy that targets selectively the action of a single
cytokine molecule, and yet by contrast a profound synergism when it is used in
combination with other therapies (Ueda et al 1990).
Lymphokines are cytokines that contribute to allo-specific immunity. They are
produced locally by activated helper T lymphocytes upon exposure to foreign MHC
class II antigens expressed both within the allograft and by migrating donor dendritic
cells in host lymphoid tissue. Lymphokines such as interleukin 2 (IL-2), IL-10 and
transforming growth factor-beta (TGF-beta) promote differentiation and proliferation
of lymphocytes and activate other cells including neutrophils and macrophages.
Cytokines that regulate natural immunity are produced by mononuclear phagocytes
and are called monokines (e.g. interleukin-1 (IL-1), interleukin-6 (IL-6) and TNF-
alpha). Monokines serve as important co-stimulators ofT cell activation during acute
allograft rejection. They also mediate activation of endothelial cells (to facilitate
leucocyte adhesion) and the coagulation cascade.
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Interferon-gamma (IFN-y) is a prime example of a third group of cytokines. These
are produced by activated T cells and serve to stimulate macrophages and upregulate
MHC class II antigen expression on endothelial cells.
Other important mediators of the immune response include adhesion molecules
(selectins, integrins, vascular cell adhesion molecule (VCAM), intercellular adhesion
molecule (ICAM)), vasoactive hormones (endothelin, prostaglandins, platelet
activating factor (PAF)) and growth factors (platelet-derived growth factor (PDGF)
insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF)).
The TGF-beta family of cytokines regulates a number of processes including cell
proliferation, angiogenesis, inflammation, immune regulation, and extracellular
matrix production and remodelling (Kitamura et al 1997). TGF-beta does not act
alone, rather it works in association with other factors such as PDGF and fibroblast
growth factor (FGF) (Roberts et al 1990). TGF-beta exists in three isoforms in
mammals: TGF-beta 1, 2 and 3. These perform similar functions in vitro, but TGF-
beta 1 is the principal isoform involved in fibrogenesis in vivo (Border et al 1994).
TGF-beta 1 is produced by a wide variety of cells including monocytes and
lymphocytes, renal tubular cells and vascular endothelium. It is transported in the
circulation within the alpha granules of platelets and is released in a latent form
bound noncovalently to another dimer peptide, the latency-associated peptide (LAP).
Active TGF-beta 1, a 25-kDa dimer protein composed of two subunits linked by a
disulphide bond, is released by the action of enzymes such as thrombospondin.
Decorin, a proteoglycan present in the extracellular matrix ofmost tissues, is thought
to act as an effector molecule in a feedback loop regulating TGF-beta 1 production
(Border et al 1994).
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The chemoattractant and immunosuppressive properties of TGF-beta 1 are evident at
low levels of expression. At higher levels of expression, TGF-beta 1 contributes to
wound healing and fibrosis via fibroblast migration, collagen synthesis and inhibition
of collagenases and other metalloproteinases. TGF-beta 1 autoinduces its own
production, thus amplifying its biological actions. Sustained activity produces
arteriosclerosis (through myofibroblastic transformation) and fibrosis, two of the key
histopathological features ofCAN (Border etal 1994).
There are several independent sources of evidence to support the notion that TGF-
beta plays a central role in the development of allograft fibrosis.
Firstly, 'high producer' TGF-beta 1 genotypes in both the organ donor and the
recipient are associated with chronic rejection in heart, lung and liver transplantation
(Awad et al 1998; Bathgate et al 1998; Densem et al 2000). A study of 100 renal
allograft recipients in Manchester revealed that all patients who developed CAN
within 5 years of transplantation (n = 9) had a 'high producer' TGF-beta 1 genotype
(Sankaran et al 1999). However, the frequency of the 'high producer' genotype in the
remainder of the study population was not stated. 8 of the 9 donors were also 'high
producers', supporting the notion that the magnitude of TGF-beta 1 production by
cells of donor origin is also of prognostic importance.
Secondly, in vivo studies of TGF-beta gene transfection into porcine arteries have
demonstrated that TGF-beta expression correlates with extracellular matrix synthesis
and intimal hyperplasia (Nabel et al 1993). Transgenic mice that overexpress TGF-
beta in hepatic tissue develop generalised tissue and organ fibrosis (Sanderson et al
1995). Similarly, the degree of glomerulosclerosis and tubulo-interstitial fibrosis in
rodent models of glomerulonephritis is proportional to the amount of glomerular
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TGF-beta activity (Yamamoto et al 1994). TGF-beta mRNA expression in the
vascular wall of rat aortic allografts is increased markedly during the proliferation
phase of chronic rejection (Little et al 1999).
TGF-beta 1 expression in the glomerular tuft and tubulointerstitium does not precede
the development of CAN in all cases, but it is a consistent finding in more
established lesions (Shihab et al 1995; Stegall et al 2001; Hueso et al 2001).
Comprehensive gene expression profiles produced by GeneChip microarray
technology have been invaluable in this area of research. Laboratory detection of
fragments ofDNA or RNA had depended until recently on the use of labelled DNA
probes with complementary sequences. The probes are able to bind selectively to the
fragments of specific interest. It is now possible to miniaturise this method, such that
tens of thousands of specific DNA or RNA sequences can be detected
simultaneously on a small glass or silica slide only 1-2 cm square (a microarray). The
technology is relatively new, but reliability is improving with the advent of a
photolithographic method of slide preparation (Aitman 2001).
Further evidence of the important role of TGF-beta 1 comes from in vitro studies of
arteriosclerosis showing that intimal thickening of arterioles is less marked when
production of TGF-beta 1 and platelet-derived growth factor (PDGF) is inhibited by
rapamycin (Gregory et al 1993).
Strutz et al have demonstrated that TGF-beta 1 promotes transdifferentiation of
tubular epithelial cells into mesenchymal cells (myofibroblasts) in vitro, which are
capable of producing extracellular matrix proteins such as fibronectin and collagen
type I (Strutz et al 2000).
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Finally, neutralising anti-TGF-beta antibodies are able to suppress inflammation in
an animal model of acute mesangial proliferative glomerulonephritis when
administered at the time of disease induction. Extracellular matrix deposition and
other histopathological features of the disease are markedly attenuated (Border et al
1990). The proteoglycan decorin, a matrix component that regulates TGF-beta
activity, has been shown to inhibit extracellular matrix production in similar
experiments (Border etal 1992).
TGF-beta 1 mRNA production is thought to be influenced by angiotensin II and
oxidised low-density lipoproteins (Ketteler et al 1995; Ding et al 1997). Activated
cytotoxic T lymphocytes that are exposed to TGF-beta 1 express a cell surface
antigen (CD103) that binds to E-cadherin, an epithelial cell-specific adhesion
molecule. TGF-beta 1 may therefore promote adhesion of T lymphocytes to tubular
epithelial cells with subsequent tubulocytolysis (Hadley et al 1997).
Active TGF-beta 1 is often detectable in the plasma during episodes of acute
rejection and CMV infection. It has been reported that 25% of renal allograft
recipients have detectable plasma levels of TGF-beta 1 within the first post-
transplant year (Williams et al 1995). TGF-beta 1 production is thought to be
increased in patients treated with CsA (Ahuja et al 1995; Shin et al 1998) but not in
those who receive tacrolimus (Hutchinson 1999). Other evidence suggests that the
former observation may be an epiphenomenon resulting from a more enhanced
release of platelet TGF-beta 1 in the presence of CsA (Brenchley et al 1998). The
expression of receptors for TGF-beta 1 is increased in the presence of CsA
(Hutchinson 1999) whereas tacrolimus disrupts TGF-beta 1 receptor activity by
binding to one of its components (FK binding protein) (Okadome et al 1996).
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As discussed previously, the magnitude of cytokine release from activated
lymphocytes (and hence the immunoresponsiveness of an individual) depends partly
on genotype (Hutchinson et al 1998). A 'high producer' TNF-a genotype may be a
predisposing factor for the development of acute allograft rejection, particularly in
combination with a 'low producer' genotype for the anti-inflammatory cytokine
interleukin-10 (Turner et al 1997). This is not a consistent finding, for example
Marshall et al recently studied 209 cadaveric renal transplant recipients and were
unable to demonstrate an association between recipient cytokine genotype and acute
rejection within the first 30 days post-transplantation (Marshall et al 2000). This
study can be criticised in terms of there being a high overall rate of acute rejection
(perhaps 'masking' the truly 'high-risk' population) and a failure to analyse the
effect on outcome of combinations of cytokine genotypes. The latter would have
been difficult to perform given the limited size of the study population. A 'high
producer' TGF-beta 1 recipient genotype may be associated with frequent and severe
acute rejection episodes and chronic rejection (Sankaran et al 1999; Buscaroli et al
2001) but again there are other studies that have produced contradictory results. For
example, a recent study by Lacha et al found that patients with a 'low producer'
TGF-beta 1 genotype had the poorest clinical outcomes (number of acute rejection
episodes and development ofCAN), especially in association with a 'high producer'
TGF-beta 1 donor genotype (Lacha et al 2001).
Polymorphisms in the promoter, enhancer and leader sequences of the TGF-beta 1
gene may influence TGF-beta 1 production (Figure 2). Codon 10 encodes part of an
alpha-helical structure that directs transport of the TGF-beta 1 protein through cells.
In the allelic variant of codon 10, proline is exchanged for leucine resulting in
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distortion of the alpha helix. The allelic variant of codon 25 is associated with
impaired cleavage of the leader sequence of TGF-beta 1, thereby preventing TGF-
beta 1 release from cells.
A comprehensive knowledge of donor and recipient genotypes may serve in the
future as a useful guide to the selection of an optimal immunosuppressive regimen
for individual patients.
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Figure 2. The location and structure of the TGF-
beta 1 gene
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4.5 Cyclosporin nephrotoxicity or CAN?
Cyclosporin (CsA), a cyclical polypeptide metabolite of the fungus Trichoderma
polysporum, was the first of a generation of immunosuppressive agents that suppress
selectively the activation of T cells. This effect is achieved primarily by impairing
the autocrine production of T cell growth factors such as interleukin 2 (IL-2).
Transcription of IL-2 is increased following dephosphorylation of nuclear factor of
activated T cells (NFAT), which migrates to the cell nucleus and binds to the EL-2
promoter region. Dephosphorylation of NFAT is a rate-limiting step that requires
calcineurin, a calcium-sensitive serine-threonine phosphatase. CsA binds to
intracellular cyclophylins and the resultant complex binds to calcineurin, thereby
inhibiting its activity. CsA has other immunomodulatory effects (some of which
paradoxically enhance immunoactivation) that are less well defined.
It is extremely disappointing that the lower rates of acute transplant rejection seen
after CsA was introduced to immunosuppressive regimens in the early 1980s have
not led to a more substantial improvement in long-term renal allograft survival
(Schweitzer et al 1991, Thorogood et al 1992). The prevailing view that CsA has an
unfavourable effect on long term outcome has been called into question by recent
data from the USA (Hariharan et al 2000). The issue is difficult to resolve for two
main reasons.
Firstly, there is insufficient comparative follow-up data (beyond 5 years post-
transplant) for groups of patients that have received different immunosuppressive
regimens (CsA-based and others). A 10-year follow-up study reported by the
European Multicentre Trial Group found no significant difference in graft attrition
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rate after the first transplant year for prednisolone/ CsA and prednisolone/
azathioprine (AZA) regimens (Beveridge et al 1995). Similar findings have been
reported by Vanrenterghem (Vanrenterghem et al 1996). A comparison ofover 4,000
CsA-treated transplant recipients and over 10,000 historical 'controls' treated with
AZA/ prednisolone (taking data from thirteen selected studies) found no significant
difference in rates of graft failure or functional attrition (Lewis 1995). The latter
finding is supported by a recent study by Velosa et al that reported a mean annual
reduction in GFR of 3ml/min for both CsA and non-CsA treated groups of renal
transplant recipients with CAN (Velosa et al 2001). It may be concluded, therefore,
that CAN rather than chronic CsA nephrotoxicity is the pre-eminent pathological
process preventing a more uniformly successful long-term graft outcome. However,
there is some evidence that for individual patients the degree and variability of
systemic exposure to CsA may be of prognostic importance. Several groups have
reported an association between low cumulative CsA dose and CAN (Schroeder et al
1995; Citterio et al 1998; Opelz et al 2001). Retrospective data collected by the
Collaborative Transplant Study Group indicate that graft survival is also reduced in
patients with a very high CsA exposure, as measured by their weight-adjusted CsA
dose at one year post-transplant (Opelz et al 2001). It has also been shown from
pharmacokinetic studies that patients who display a high variability ofCsA exposure
have a significantly increased risk of developing CAN (Kahan 1998). Studies of
elective post-transplant withdrawal ofCsA have given conflicting results in terms of
graft outcome (Kasiske et al 1993; Hollander et al 1995; Opelz 1995; Stoves et al
2002a). This is attributable in part to differences in case selection and CsA
withdrawal protocols.
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The second reason for uncertainty regarding the long-term effects of CsA relates to
the difficulty in discriminating between the clinico-pathological features of chronic
CsA nephrotoxicity and CAN (Mihatsch et al 1995). For example, both are
associated with hypertension and the clinical features ofCsA toxicity such as tremor,
gingival hyperplasia and renal tubular hyperchloraemic acidosis may not be evident.
Both processes involve blood vessels and the tubulointerstitial space and distinctive
histopathological features (see below and Section 4.2) may be absent, such that only
non-specific end-stage abnormalities such as arterial intimal fibrosis, arteriolar
hyalinosis, intraglomerular fibrin thrombi, irregular tubular vacuolation and
generalised interstitial fibrosis are seen. A consideration of some general points may
be of diagnostic value. Firstly, CsA nephrotoxicity is predominantly an arteriolar
lesion whereas CAN typically affects larger vessels. Secondly, CsA nephrotoxicity
commonly involves the tunica media with myocyte loss and replacement by hyaline
deposits, whereas CAN is primarily a proliferative intimal disorder with cellular
infiltration. Glomerular features such as lobulation and reduplication of the capillary
basement membrane are more typical ofCAN. Finally, the presence of an interstitial
infiltrate of inflammatory cells (lymphocytes, macrophages and plasma cells) would
favour a diagnosis ofCAN.
In attempting to discriminate between the two pathological processes, it must be
recognised that CsA may itself contribute to the development and progression of
CAN. Previous work in mice has shown that CsA inhibits the development of
tolerance induction by mycophenolate mofetil (see Section 4.6.1) (Hao et al 1992).
There is also some evidence that CsA has a stimulatory effect on B cells in vitro, thus
promoting plasma cell differentiation and IL-6 release (Wortley et al 2001). The
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effect of CsA on TGF-beta 1 production is discussed later in this section (and in
Section 4.4).
What is the precise mechanism of 'pure' CsA nephrotoxicity? It is well known that
treatment with CsA is associated with an acute dose-related decrease in renal
function in both experimental animals and human volunteers (Bennett et al 1996).
The rapid reversibility of this effect when CsA is withdrawn (Curtis et al 1986)
suggests that it does not represent a primary toxic insult to renal tubular cells, rather
an alteration in intrarenal vascular resistance that is mediated predominantly by
vasoconstriction of the afferent glomerular arteriole. CsA is known to disturb many
of the vasoactive systems that control renal vascular tone and GFR including nitric
oxide, endothelin, prostaglandins and platelet activating factor (PAF), and it may
also have a direct effect on the tonicity of vascular smooth muscle cells and
mesangial cells (Cairns et al 1998). The histological features of acute CsA
nephrotoxicity are consistent with acute ischaemic injury and include hyalinosis and
myocyte necrosis of renal arterioles and isometric vacuolisation of renal tubular
cells.
Chronic exposure to CsA may produce permanent nephrotoxicity. The
histopathological features of chronic CsA toxicity in renal allografts include striped
tubulointerstitial fibrosis, tubular atrophy and nodular hyperplasia of afferent
arterioles (Feutren et al 1992). These features are seen first in the renal medulla with
later extension to the medullary rays of the cortex. Klintmalm et al found more
severe interstitial fibrosis and tubular atrophy in CsA-treated versus non-CsA-treated
renal transplant recipients (Klintmalm et al 1984). The histopathological features
correlated with CsA trough levels and the cumulative prescribed CsA dose during the
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first 6 months post-transplant but were evident even in allografts of patients
receiving doses of less than 4 mg/kg/day. CsA dose reduction or withdrawal is
associated with a partial resolution of CsA-related arteriolopathy but persistence of
the tubulointerstitial features (Bennett etal 1986).
Chronic CsA nephrotoxicity was described in cardiac allograft recipients as early as
the mid-1980s (Myers et al 1984). Myers subsequently reported that the prevalence
of ESRF within 10 years of heart transplantation was approximately 10% (Myers et
al 1991). Glomerulosclerosis is a typical histopathological feature in addition to the
vascular and tubulointerstitial changes that occur in renal allografts. It is likely that
the kidneys of heart transplant recipients are chronically ischaemic, leading to
upregulation of the renin-angiotensin system and consequently an exacerbation of
CsA-induced renal fibrosis as discussed later in this section.
CsA nephrotoxicity is a major cause of progressive renal dysfunction in lung and
heart-lung transplant recipients (Zaltzman et al 1992; Pattison et al 1995). In a study
of 30 lung transplant recipients who were followed-up for a minimum period of 6
months, 50% developed hypertension, 30% had serum creatinine measurements of
above 3 mg/dl (250 umol/1) and 2 reached ESRF.
Following liver transplantation, GFR decreases almost immediately to about 45-60%
of normal but then remains stable for several years (Wheatley et al 1987; Platz et al
1994). A similar incidence and pattern of nephrotoxicity is described with the
calcineurin inhibitor tacrolimus (FK506).
CsA is used in bone marrow transplantation to prevent graft versus host disease. In a
histopathological study of CsA-treated bone marrow transplant recipients that
included autopsy specimens, Dieterle et al found striped interstitial fibrosis and
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arteriolopathy in 50% and 70% of cases respectively. The severity of these lesions
correlated with the duration of CsA therapy. Serum creatinine measurements tended
to rise by 40 - 80% within 3 months of commencing CsA and then stabilise (Dieterle
et al 1990).
CsA has been used in the treatment of various glomerular disorders. Meyrier et al
found that patients with minimal change nephrotic syndrome receiving CsA doses of
up to 5.5 mg/kg/day did not develop histological features of CsA nephrotoxicity.
Although similar results were reported for a group of CsA-treated patients with focal
glomerulosclerosis (FSGS), renal function deteriorated in some patients (especially
those with pre-existing renal dysfunction). This was due in part to exacerbation of
the underlying renal pathology (Meyrier et al 1994).
Although relatively low doses of CsA are used in the treatment of autoimmune
disease and rheumatoid arthritis, interstitial fibrosis and other changes of chronic
nephrotoxicity tend to occur within 2 years of commencing treatment (Sund et al
1994). It has been shown in long-term studies that the histological features are
progressive (Young et al 1994). The most frequently occurring lesions are
glomerular collapse, arteriolar hyalinosis, tubular atrophy and interstitial fibrosis
(Mihatsch et al 1994). A meta-analysis and morphological review of CsA-induced
nephrotoxicity in conditions such as rheumatoid arthritis, psoriasis, atopic dermatitis
and Crohn's disease found that the weighted percentage increase in serum creatinine
was 17% in CsA-treated patients and 1.7% in 'control' patients who did not receive
CsA (Vercauteren et al 1998). An incomplete reversal of renal dysfunction following
withdrawal ofCsA was reported in some patients. According to Feutren et al, a high
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CsA dose (above 5mg/kg/day) and increasing patient age are the main predictors of
chronic CsA nephrotoxicity (Feutren et al 1992).
The anti-fibrotic drug pirfenidone has been shown to decrease TGF-beta 1 expression
and ameliorate fibrosis in the salt-depleted rat model of CsA nephrotoxicity (Shihab
et al 2001). Salt depletion may upregulate the expression of angiotensin II-dependent
lymphokines and fibroblast growth factors, thus providing a link between acute
vasomotor changes and chronic tubulo-interstitial damage (Wolf et al 1993). CsA
increases the recruitment of renin-producing cells along the afferent glomerular
arteriole (Tufro-McReddie et al 1993; Moore et al 1995). Johnson et al have
demonstrated in rats that angiotensin II infusions can produce tubulo-interstitial
changes similar to those seen with chronic CsA nephropathy (Johnson et al 1992).
Furthermore, the angiotensin II type I receptor is located in the outer medulla and the
medullary rays, mirroring the distribution of lesions in the animal model of chronic
CsA toxicity (Meister et al 1993).
Although renal vasoconstriction is seen as the most likely cause of the
histopathological changes of CsA nephrotoxicity, in vitro studies have shown that
other mechanisms may be important. For example, even small doses ofCsA promote
the synthesis of extracellular matrix components such as collagen type III (Ghiggeri
et al 1994; Oleggini et al 2000). There is also evidence that CsA stimulates
production of TGF-beta 1, a cytokine that has both immunosuppresive and fibrogenic
properties (Shihab et al 1996) (see Section 4.4). TGF-beta 1 expression decreases in
patients with CAN who undergo CsA withdrawal or CsA dose reduction (Wei et al
1998; Hueso et al 1998).
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In addition to nephrotoxicity, CsA treatment is associated with hypertension and
hyperlipidaemia. These are major risk factors for ischaemic cardiovascular disease,
which has a major impact on patient survival and hence renal allograft survival. CsA-
induced stimulation of the renal sympathetic nervous system may be one mechanism
by which hypertension develops in recipients of non-renal organ transplants. It has
been suggested that the denervation that occurs during procurement of a donor
kidney ameliorates this effect in renal transplantats (Mark 1990) but the theory is
refuted by strong experimental evidence and is therefore unlikely to be a significant
factor (Remuzzi et al 1995).
CsA is metabolised extensively in the liver by the enzyme cytochrome P450-3A4.
Metabolites are excreted primarily via the hepatobiliary system. The large inter- and
intra-individual variability of CsA absorption (less marked for the microemulsion
CsA formulation, Neoral®) makes dose monitoring difficult. Several metabolites of
CsA (including M-17) may produce nephrotoxicity. Most of the laboratory assays
that are used to measure the concentration of CsA in venous blood detect only the
parent compound, and this is clearly an important limitation which needs to be
recognised when using blood CsA concentrations as a guide to CsA dose adjustment.
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4.6 Options for treatment of CAN
There are currently no effective strategies for the prevention or treatment ofCAN in
human subjects other than measures to minimise the impact of risk factors such as
poor HLA matching, ischaemia-reperfusion injury, acute rejection, CMV infection,
hypertension, hypercholesterolaemia and CsA nephrotoxicity (see Section 4.1).
Clinical trials of immunosuppressive agents other than CsA will be discussed in this
section, followed by a review of the role of ACE inhibitors and finally a summary of
experimental approaches to the treatment ofCAN.
4.6.1 Mycophenolate mofetil
Mycophenolate mofetil (MMF) is the morpholinylester of mycophenolic acid
(MPA), a potent inhibitor of T and B lymphocyte proliferation. MPA also
downregulates antibody production (of potential importance in the treatment of
CAN) and the expression of cell-surface adhesion molecules that promote binding of
lymphocytes to vascular endothelial cells at sites of inflammation (Grinyo 1999). It
inhibits specifically the enzyme inosine monophosphate dehydrogenase, a critical,
rate-limiting factor in the so-called 'de novopathway' of purine synthesis.
MMF is effective in preventing early, acute renal allograft rejection (Tricontinental
Mycophenolate Mofetil Renal Transplant Study Group 1996 and 1998; European
Mycophenolate Mofetil Cooperative Study Group 1995 and 1999). In the
Tricontinental study, 503 newly transplanted patients were randomised to receive
azathioprine (AZA) 100 - 150 mg/day, MMF 2g/day or MMF 3g/day in addition to
prednisolone and CsA. During the first 6 months post-transplant, the incidence of
biopsy-proven acute transplant rejection was reduced by approximately 50% in the
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MMF 2g/day (19.7%) and MMF 3g/day (15.9%) groups as compared to the AZA
group. There was also a significant reduction in treatment failure (persistent
rejection, death, graft loss or early withdrawal with no prior acute rejection
episodes). Graft function (intent-to-treat and on-study) was comparable in all three
groups at 3 years, as was patient mortality.
In the European double-blinded, placebo-controlled study, 491 patients were
randomised to placebo, MMF 2g/day or MMF 3g/day in addition to prednisolone and
CsA. Significantly fewer patients had biopsy-proven rejection in the first 6 months
post-transplant with MMF 2g/day (17%) and MMF 3g/day (13.8%) as compared to
placebo (46.4%). An advantage in respect of other causes of early treatment failure
(see above) was also reported. At 3 years post-transplant, MMF was associated with
a 7.6% reduction in the incidence of graft loss (excluding graft loss resulting from
patient death).
A meta-analysis of three major studies (European, Tricontinental and an American
study) showed that graft loss due to rejection for a control group of patients receiving
a regimen of steroids and CsA with or without AZA was 6.3% in the first post¬
transplantation year, whereas the groups receiving steroids, CsA and MMF at doses
of 2g/day and 3g/day had corresponding graft loss rates of 2.6% and 3.5%
respectively (Halloran etal 1997).
MMF has been used effectively in transplant recipients for whom there is a high risk
of acute rejection and/or CsA nephrotoxicity (Agraz et al 1999; Esmeraldo et al
1999). It has also been used in combination with other agents for the treatment of
refractory acute rejection (Mycophenolate Mofetil Renal Refractory Rejection Study
1996; Mycophenolate Mofetil Acute Renal Rejection Study Group 1998; Carl et al
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1998). The main side effects of MMF are dose-related gastro-intestinal symptoms
including nausea, abdominal pain and diarrhoea and myelosuppression.
MMF has reversed some of the histopathological features of CAN in both renal and
aortic allograft models of chronic rejection in the rat (Raisanen-Sokolowski et al
1994; Azuma et al 1995). A reduction in interleukin-2 expression was documented in
the former study. Therapeutic concentrations of MMF inhibit the growth of
fibroblasts in cell culture studies. This effect is mediated by an increase in apoptotic
activity (Zeier et al 2002). MMF may also prevent the progression of renal
insufficiency in rats that undergo 5/6 renal ablation (Romero et al 1999). There are
obvious limitations associated with animal model experiments and long-term
outcome data are generally unavailable.
Recent pilot studies have addressed the clinical effectiveness of MMF in the
treatment of established CAN. The choice of MMF may have been encouraged by
evidence from earlier studies that late introduction of AZA (another antiproliferative
agent) to dual therapy (CsA/prednisolone) regimens had a beneficial effect on graft
outcome (Rocher et al 1989; Kliem et al 1998). Rocher et al studied 21 patients with
CAN (not biopsy-proven in all cases) in whom AZA was commenced at 17.8 +/- 2.8
months post-transplantation. CsA dose was not reduced. There was an improvement
in renal function following the introduction of AZA (p<0.01) with no significant
change in blood CsA trough levels. Kliem et al reported a favourable response to
AZA in combination with CsA dose reduction. The latter is of course a potential
confounding factor. Both studies are weakened by the absence of a control group and
Kliem's study was in part retrospective.
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Weir et al studied the clinical course of28 CsA-treated renal allograft recipients with
suspected CAN (diagnostic confirmation from transplant biopsy was not obtained in
all cases) whose immunosuppressive regimen was changed at 24.3 ± 7.7 months
post-transplantation (Weir et al 1997). MMF 2g/day was substituted for AZA and the
CsA dose was halved. The dose of MMF was reduced subsequently in 8 patients
because of gastrointestinal toxicity and/or anaemia. No patients received angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II receptor blockers. Renal
function improved in 21 patients according to measurements of serum creatinine and
there was a significant reduction in the mean serum cholesterol concentration. Not all
patients had biopsy-proven CAN and it is not clear in what proportion of patients
there was histological evidence of co-existent acute rejection. There were no control
patients and the majority of study participants were male African-Americans. MMF
conversion was initiated at different times post-transplantation across the study
population. Follow-up was of variable duration, though generally of sufficient length
to allow adequate assessment of outcome. A reliable method of measuring GFR was
not employed.
Islam et al studied 43 transplant recipients with CAN (not all biopsy-proven) who
were treated with MMF and reduced dose CsA to achieve a trough blood CsA level
of 50 ng/ml (Islam et al 1998). The mean observation period was 15 (6-22) months.
MMF was discontinued because of diarrhoea in 3 patients and infection and anaemia
in 2 patients. Two patients suffered graft loss as a result of worsening chronic
rejection. There was a significant improvement in mean serum creatinine from 3.14 +
1.0 to 2.57 + 0.82 mg/dl (p<0.01). Once again, the study was small and uncontrolled.
Several patients were excluded from the final analysis because of insufficient follow-
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up. Not all study participants had biopsy-proven CAN. Renal function was measured
using serum creatinine rather than isotope methods. There was no reference to the
use of statin or ACE inhibitor medications during the study period.
Two earlier American studies in which CsA was not simultaneously reduced failed to
demonstrate a significant benefit from the addition of MMF, suggesting that CsA
dose reduction may have been the key component ofWeir's regimen (Glicklich et al
1998; Smith et al 1997). The latter could be explained readily in terms of a
favourable alteration in renal haemodynamics as CsA is known to produce
vasoconstriction of afferent glomerular arterioles (Curtis et al 1986). Evidence in
support of this theory is provided by a study of patients with biopsy-proven CsA
nephrotoxicity without CAN by Houde et al. This demonstrated that conversion from
a CsA/ prednisolone regimen to a MMF/ prednisolone regimen at 57 (12-109)
months post-transplant was safe and led to improved graft function and better control
of hypertension and hyperlipidaemia (Houde et al 2000). The same approach has
been successful in CsA-treated patients with progressive chronic renal allograft
dysfunction (Suwelack et al 2001; Dudley 2002). The Creeping Creatinine Study has
examined the effect of introducing MMF followed by complete withdrawal of CsA
in patients with biopsy-proven 'chronic allograft dysfunction' (this is clearly a
misnomer and we await clarification in a forthcoming full publication). It is unique
in having a control arm. Preliminary results show that renal function stabilised in
58% of patients receiving MMF in place of CsA (n = 73) as compared to only 28%
of controls (n = 70) (Dudley et al 2002).
The results of other recent studies indicate that MMF may have a direct effect on the
progression of chronic renal allograft dysfunction in patients with CAN. A
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retrospective registry-based study of 66,774 renal transplant recipients (1988-1997)
by Ojo et al found that MMF reduced the risk of CAN by 27% compared to AZA
(Ojo et al 2000). This was not due entirely to a concomitant reduction in the number
of acute rejection episodes. Death-censored graft survival for patients receiving
MMF was significantly higher than for those receiving AZA (85.6% v.v 81.9% after 4
years). As with all retrospective analyses, there are many potential sources of bias in
this study that may not have been considered. Fritsche et al studied 44 patients with a
diagnosis of chronic rejection in whom MMF treatment was initiated at 5.8 + 4.8
years following renal transplantation (Fritsche et al 1998). MMF was substituted for
AZA in the majority of cases. The overall rate of decline in GFR was reduced
significantly during the follow-up period (10.1 + 4.9 months). A reduction in MMF
dose was necessary in 10 patients, mainly because of gastro-intestinal side effects.
The study was partly retrospective and there were no control patients. Not all patients
had previously been taking CsA. MMF conversion was initiated over a wide-ranging
period post-transplantation and follow-up was of variable duration. It was not made
clear how GFR had been calculated and there was no reference to concomitant use of
statin or ACE inhibitor medication, both of which may have influenced clinical
outcome. In an uncontrolled prospective study performed by Kliem et al, MMF
2g/day was added to a baseline regimen of prednisolone and CsA in 40 renal
transplant recipients with CAN at a median of 82 (11-192) months following renal
transplantation (Kliem et al 1999). Follow-up was of extremely variable duration
(0.25 - 14 months). There were no episodes of acute rejection but 3 patients lost their
graft as a result of persisting CAN. Of the 26 patients who were followed for more
than 5 months, 15 showed stable or improved graft function (although this was not
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measured by a reference method). Once again, there was no information about the
use of statin or ACE inhibitor medications during the study period. MMF was
discontinued in 6 patients (permanently in 3 cases) and the dose reduced in a further
8 patients because of gastro-intestinal side effects, leucopaenia and anaemia. In
another uncontrolled study of 31 allograft recipients with biopsy-proven CAN who
commenced MMF treatment at 52 + 38 months post-transplant, 23 patients showed
stability or improvement of renal function according to serum creatinine
measurements (Campistol et al 1999). This change was not accompanied by a
reduction in arterial hypertension or proteinuria. The mean trough CsA blood
concentration for the group as a whole was lower at the end of the study period than
at the beginning, but a sub-group analysis ofpatients in whom CsA trough levels had
remained stable gave similarly encouraging results. Finally, a prospective, multi¬
centre study in Spain involving 122 CsA-treated patients with biopsy-proven CAN
showed that the addition of MMF (replacing AZA in a half of cases) protected
against graft loss, although once again there was no control group (Gonzalez Molina
et al 2001). The majority of patients had Banff grade II or grade III transplant biopsy
scores. Renal function was measured by serum creatinine. Multiple regression was
used to calculate the slope of the 'reciprocal of creatinine versus time' (ROCT) plots
for the pre-intervention and post-intervention periods. The median duration of
follow-up was 18 months. MMF was discontinued in 18 patients because of
unwanted side effects. The median values of the ROCT slopes for the whole group
before and after the introduction of MMF were -2 x 10"4 and -7 x 10"6 (units not
provided) respectively (p<0.001). The difference remained significant when only
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AZA-treated patients were considered and also when the analysis was limited to the
65 patients who had no change in CsA trough levels throughout the study period.
In summary, the majority of reported studies ofMMF +/- CsA dose reduction for the
treatment of CAN, though encouraging, are weakened by small size, loose inclusion
criteria, use of suboptimal methods of measuring kidney function and a failure to
include 'control' patients who do not undergo immunosuppression conversion. The
latter is essential if bias relating to the potential benefits of study participation is to
be minimised. These issues are addressed further in Chapter 4.
4.6.2 Tacrolimus (FK506)
Tacrolimus (FK506) is a macrolide metabolite of the fungus Streptomyces
tsukabaensis. It inhibits T cell activation and T cell-dependent proliferation of B
cells, principally through its ability to bind to intracellular immunophilins such as FK
binding protein 12 (FKBP12). The resultant complexes bind specifically and
competitively with calcineurin, thereby blocking activation of the NFAT pathway.
Tacrolimus suppresses T cell activation in other ways such as blockade of cytokine
receptor expression on target cells (Mori et al 1997). Oral absorption of tacrolimus is
incomplete and there is a high degree of pre-systemic metabolism, principally by the
cytochrome P450 enzyme CYP3A4 contained within enterocytes. The main
metabolic pathways are hydroxylation and demethylation. The immunosuppressive
activity of the parent compound far exceeds that of its metabolites.
Several studies have demonstrated that tacrolimus is a safe and effective
immunosuppressant for renal transplant recipients (Jensik et al 1998; Mayer 1999).
The incidence of both acute and chronic rejection is less than for CsA-based
68
regimens, although the trend for chronic rejection has not reached statistical
significance even in large studies with several years of follow-up (Mayer et al 1997;
Mayer 1999; Pirsch 2000). Patient and graft survival rates are comparable to those
reported with CsA. However, if crossover due to rejection is considered as graft loss,
3-year graft survival is significantly higher in patients treated with tacrolimus (81.5%
vs 70%, p<0.05) (Mayer 1999).
Tremor, diarrhoea and glucose intolerance are some of the more common adverse
effects of tacrolimus. There is a lower incidence of acne, hirsutism and gingival
hyperplasia in comparison to CsA-treated patients (Mayer et al 1997). Successful
withdrawal of steroid treatment has been possible in a large proportion of patients
treated with tacrolimus (Cronin et al 1997; Shapiro et al 1998; Buell et al 2000).
The most comprehensive outcome data for patients treated with CsA-based and
tacrolimus-based immunosuppression regimens are provided by the US Kidney
Transplant Registry. A review of over 38,000 CsA-treated and 500 tacrolimus-
treated patients indicated a significant graft survival advantage for the latter group
(Gjertson et al 1995). One-year graft survival in the CsA and tacrolimus groups was
86.6 + 0.2% and 91.1 + 1.3% respectively. Graft half-life estimations were
approximately 9 years with CsA and 14 years with tacrolimus (p<0.05). The finding
of superior graft survival with tacrolimus-based immunosuppression is supported by
data from a prospective randomised study reported by Laskow, who also
demonstrated that graftfunction at 3 years post-transplant was superior in tacrolimus-
treated patients (Laskow 1999).
It has recently been reported by the European Tacrolimus Renal Registry Study
Group that conversion from CsA to tacrolimus at the time of a first acute rejection
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episode facilitates reversal of rejection and subsequently provides effective
secondary prevention (Briggs 2000).
Pilot studies of substituting tacrolimus for CsA in patients with CAN have been
encouraging, although the findings are inconclusive because of their small size, the
absence of control groups and suboptimal measurement of transplant function. Of 14
renal allograft recipients who were converted to tacrolimus at a median of 1,750 days
post-transplant with a mean pre-conversion GFR of 21.4 ±9.1 ml/min, 5 showed
stability or improvement of function (Morris-Stiff et al 1998b). Other studies have
produced similar results but sample sizes have again been relatively small (Manu et
al 1999).
4.6.3 Rapamycin
Rapamycin (RPM) reduces proliferation of T lymphocytes, B lymphocytes and some
non-lymphoid cells by reducing cyclin-dependent kinase activity (Halloran 1996).
For example, in vitro studies have shown that RPM inhibits endothelial cell and
smooth muscle cell proliferation (Gregory et al 1993; Morris et al 1995). RPM binds
to the mammalian target of rapamycin (mTOR) and blocks both the costimulation
cascade that augments interleukin-2 gene transcription (in the GO to G1 transition
phase of the cell cycle) and the cytokine transduction pathway (in the late G1 phase)
(Abraham 1998).
There is as yet no reported clinical experience of RPM in the treatment of patients
with CAN. In a rat aortic graft model of chronic rejection, RPM inhibits the
development of chronic vascular changes (endothelial denudation, subendothelial
infiltration with inflammatory cells and smooth muscle proliferation) in contrast to
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the more modest effects of CsA (Belitsky et al 1993). Schmid et al examined the
effects ofRPM on transplant vasculopathy in long surviving F344 rat heart allografts
transplanted heterotopically into Lewis rat recipients (Schmid et al 1995). RPM was
administered intraperitoneal^ for the first 14 days post-transplant in groups 1 and 2
(0.5 and 2 mg/kg/day) and daily throughout the follow-up period in groups 3 (0.5
mg/kg/day) and 4 (5 mg/kg/day for 14 days, followed by a maintenance dose of 2.5
mg/kg/day). Grafts were removed from animals in group 1 at 50, 75, 100, 150 or 200
days post-transplant. Animals in the other groups underwent nephrectomy at 100
days post-transplant. Infiltrating cell populations and patterns of cell surface
molecule expression were characterised and compared between groups. In group 1,
the incidence of transplant vasculopathy increased in proportion to the age of the
graft. An infiltrate of cells expressing MHC class II antigen and upregulated
expression of adhesion molecules and cytokines were other prominent features.
Animals receiving a higher maintenance dose of RPM had a lesser degree of
transplant vasculopathy and inflammatory cell infiltrate.
4.6.4 Corticosteroids, azathioprine and antilymphocyte antibody
prophylaxis
There is no consensus regarding the effect on late renal allograft loss of
corticosteroid therapy. A study by Hollander et al of prednisolone withdrawal at one
year post-transplant reported an increased incidence of acute rejection episodes and
post-withdrawal proteinuria (Hollander et al 1997). This approach may be more
successful in combination with more potent immunosuppressive regimens.
Several studies have not shown a significant reduction in the incidence ofCAN with
addition of AZA to a dual therapy (CsA/ prednisolone) regimen, although there is a
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trend towards improved graft survival (Kunz el al 1997; Amenabar et al 1998). More
encouraging study data for patients with established CAN were presented in Section
4.6.1.
A meta-analysis of trials of antilymphocyte antibody prophylaxis has shown that the
graft survival rate at 2 years post-transplant is 5% higher than for an untreated
control group (Szczech et al 1997), perhaps implying a lower incidence of CAN. A
15-year prospective randomised controlled single-centre trial involving 123
consecutive adult cadaveric renal transplant recipients produced similar short-term
results, but there was no significant long-term (beyond 5 years) graft survival
advantage for patients receiving prophylactic antibody therapy (Cantarovich et al
2002). A recent meta-analysis of interleukin-2 receptor monoclonal antibody
(basiliximab or daclizumab) prophylaxis showed a 22% reduction in graft loss at 1
year but this was not statistically significant (Cockwell et al 2002).
4.6.5 Angiotensin converting enzyme inhibitors and angiotensin II
receptor antagonists
Angiotensin II (Ang II) is thought to play an important role in producing the vascular
lesions that are associated with CAN in addition to its role in the pathogenesis of
chronic CsA nephrotoxicity (as discussed in Section 3.5). There is experimental
evidence that Ang II promotes myofibroblastic transformation of endothelial cells,
probably via activation of TGF-beta 1 (Kagami et al 1994) and endothelin (ET-1)
(Millgard et al 1998).
Angiotensin-converting enzyme (ACE) inhibitor preparations lower both systemic
and intraglomerular pressure (Bochicchio et al 1990) and may also reduce oxidative
stress (Calo et al 2001). There is evidence that their use in patients with CAN is
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associated with a reduction in proteinuria and a slower rate of decline in renal
allograft function (Barnas et al 1996; Lin et al 2001). A retrospective study by
Barnas et al found significantly lower urinary protein excretion (fractional excretion
69+13 mg/1 at 12 months compared to 57 + 16 mg/1 at the start of treatment) and a
less rapid decline in allograft function (-9 ± 1.2 ml/min/year for the 12 months before
starting treatment compared to -4.8 + 1.3 ml/min/year for the 12 months after
starting treatment) with ACE inhibitor therapy. The study had a number of
methodological flaws, for example a transplant biopsy was not performed in some
cases and patients were used as their own controls.
Angiotensin II receptor antagonists (ATl-RAs) produce a similar response to ACE
inhibitors both experimentally (Furukawa et al 1996) and in clinical practice (Omoto
et al 2001). Furukawa et al used the AT1-RA TCV-116 in a murine model of cardiac
transplantation. Hearts ofDBA/2 mice were transplanted heterotopically into B10.D2
mice. Recipients were treated with oral TCV-116, captopril or vehicle only. At 70
days post-transplantation there was a significant reduction in the severity of graft
coronary arteriopathy in the TCV-116 group and captopril groups compared to the
vehicle group (p<0.001 and p<0.005 respectively). Fibrotic lesions of the left
ventricle were reduced significantly in the TCV-116 and captopril groups as
compared to mice receiving vehicle only. Omoto et al studied 62 proteinuric renal
transplant recipients, 28 of whom had CAN (a subgroup analysis of these patients
was not performed). The ATI-RA candesartan cilexetil was commenced at a dose of
between 4 and 12 mg daily. There was a significant reduction in proteinuria within 2
months of starting treatment that was sustained during follow-up, but serum
creatinine measurements continued to show a rising trend. The response may have
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been linked to an overall reduction in systemic blood pressure rather than a specific
intrarenal effect of candesartan.
4.6.6 Statins
Statin therapy was discussed briefly in Section 4.1. There is evidence from
experimental studies in cardiac and renal allograft recipients to support its role in the
treatment and prevention of chronic rejection.
Kwak et al demonstrated recently that statins (HMG-CoA reductase inhibitors) have
immunomodulatory effects (Kwak et al 2000). They suppress MHC class II antigen-
mediated T cell activation directly through inhibition of the inducible promoter IV of
the transactivator CIITA. This effect is observed in cell culture studies of primary
human endothelial cells, monocytes and macrophages. However, randomised clinical
studies have failed to demonstrate an effect of statins on acute renal allograft
rejection (Holdaas et al 2001, Kasiske et al 2001).
Ji et al recently studied the efficacy of pravastatin for the prevention ofCAN in rat
kidney allografts (F344 to Lewis) (Ji et al 2001). Recipients were divided into 3
groups: syngeneic (Group 1); allogeneic - CsA treatment alone (Group 2); and
allogeneic - CsA plus pravastatin treatment (Group 3). Renal function was assessed
by serum creatinine at 130 days post-transplantation. Expression of anti-apoptotic
Bag-1 products was analysed by Western blot. Group 1 rats had no histological
evidence ofCAN. Group 2 and 3 rats showed vascular obliteration, tubular atrophy,
glomerular sclerosis and interstitial fibrosis, however these features were
significantly less prominent in the pravastatin-treated group. There was also a lower
mean serum creatinine and a greater mean upregulation of Bag-1 expression in
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comparison to Group 2. The latter observation suggests that pravastatin may have a
beneficial anti-apoptotic effect.
Jaeger et al compared a combined regimen of a statin and weekly extracorporeal
HELP (Heparin-mediated Extracorporeal LDL/fibrinogen Precipitation) apheresis
to statin therapy alone in two matched groups of human cardiac allograft recipients
(Jaeger et al 1997). Graft vessel disease (GVD) was assessed by coronary
angiography over a mean follow-up period of 3.6 years. GVD was apparent in only
one patient who received the combined treatment, compared with a total of seven
patients in the monotherapy group. The combined treatment was associated with a
marked reduction in plasma levels of low density lipoprotein (LDL) cholesterol,
lipoprotein A and fibrinogen. There were no reported adverse effects of apheresis, in
particular there was no increase in the incidence of sepsis.
In a study by Kobashigawa et al, consecutive cardiac allograft recipients were
assigned randomly to a pravastatin treatment group or a control (no pravastatin
treatment) group (Kobashigawa et al 1995). Twelve months following
transplantation, the pravastatin treatment group had a lower mean serum cholesterol,
a lower incidence of allograft coronary vasculopathy (as determined by angiography
and histopathological examination of autopsy specimens) and superior allograft
survival. In addition, intracoronary ultrasound studies performed at one year post¬
transplantation revealed lesser degrees of intimal thickening in pravastatin-treated
patients.
It remains to be seen if statin therapy will be effective in prolonging graft survival
(by reducing the incidence of CAN and/or cardiovascular mortality) in human renal
allograft recipients.
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4.6.7 Dietary protein restriction
Modest dietary protein restriction improves glomerular permselectivity and may
reduce the rate of deterioration in graft function, possibly via suppression of the
renin-angiotensin system (Rosenberg et al 1995). There has not been a large
randomised controlled trial of dietary intervention in patients with established
biopsy-proven CAN. However, a randomised study of patients with advanced
chronic native renal dysfunction (Modification of Diet in Renal Disease Study)
provided some evidence that dietary protein restriction in the order of 0.6 g/kg/day
can slow the rate of decline in GFR (Levey et al 1996). This effect was shown to
depend on achieved rather than prescribed levels of protein intake. Diabetic patients
were not included in the analysis. Concerns about suboptimal nutrition were not
addressed in the study and this is probably the main reason for the reluctance of
many physicians to follow this approach in their clinical practice. A small,
uncontrolled retrospective study of dietary protein restriction in patients with chronic
rejection showed a slowing of disease progression according to pre- and post-
intervention ROCT plots (Salahudeen et al 1992).
4.6.8 Experimental therapies
The following approaches to the prevention and treatment of CAN have been
pursued in the field of animal research. Many of the experimental agents have not




Immunotolerance is the 'Holy Grail' of therapeutics in allogeneic transplantation. It
would by definition eliminate the need for maintenance anti-rejection medication.
Researchers have looked at many different components of the immune response and
used a number of experimental strategies including T cell depletion, T cell
costimulatory pathway blockade, establishment of microchimerism (the presence in
the recipient of a small number of donor lymphoid cells that circulate without being
challenged by the host immune system) and the development of 'knockout gene'
(e.g. cytokine and complement genes) animal models. A global Immune Tolerance
Network (www.immunetolerance.org) has been created to facilitate and coordinate
the development of effective strategies for achieving immunotolerance in man. The
following is a summary of the experimental evidence that bone marrow transfusion
and costimulatorypathway blockade may be effective in preventing CAN.
The first blood transfusion effect to be described was an experiment of nature.
Freemartin cattle dizygotic twins share a common placenta. It was demonstrated that
such twins had haemopoietic chimerism (Owen 1945). A skin graft from one twin
was not rejected by the other, thus contradicting the view that immunological
reactivity to foreign tissue and proteins was rigidly predetermined (Anderson et al
1951). The discovery in mice of tolerance to skin grafts following neonatal exposure
of the host to donor leucocytes can be regarded as the first blood transfusion
experiment (Billingham et al 1953). The effect of transfusing blood from a 'third
party' source prior to kidney transplantation in humans remains uncertain (Opelz et
al 1973). Salvatierra et al studied the effect of donor-specific transfusion (DST) in
living-related kidney transplants (Salvatierra et al 1987), Their key finding was that
77
early graft loss as a result of acute rejection was virtually eliminated in one HLA
haplotype mismatch donor-recipient combinations. Longer-term graft outcome was
less impressive. Importantly, DST was associated with a 10% incidence of anti-HLA
antibody generation in recipients. This changed the crossmatch result from negative
to positive, so denying many patients the potential benefits of renal transplantation.
The reduction in frequency of acute rejection episodes that was achieved with DST
became insignificant following the introduction of more effective
immunosuppressive therapies such as CsA. Further work has suggested that DST in
the case of donors who possess maternal HLA antigens not inherited by the recipient
reduces the incidence of acute transplant rejection (Burlingham et al 1998). It is
hypothesised that transfusion leads to reawakening of a T cell memory of neonatal
exposure to semiallogeneic maternal cells and soluble (not cell-bound) HLA.
Future strategies to encourage tolerance may involve donor-specific bone marrow
transfusion. It has been shown in rats (male Lewis kidney donors and female Brown-
Norway recipients) that peritransplant infusion of donor bone marrow followed by
administration of haematopoietic growth factors (including rh-granulocyte colony
stimulating factor (GCSF) and rh-IL-6) reduces the severity of subsequent CAN in
inverse proportion to the amount of detectable microchimerism that is produced
(Terakura etal 1999).
In animal models the systemic administration of CTLA4Ig, a fusion protein that
binds B7 molecules on the surface of antigen-presenting cells and therefore blocks
the B7-CD28 T-cell costimulatory pathway, induces a state of immunotolerance.
Azuma et al tested the effect of CTLA4Ig on the development of CAN in rats
(Azuma et al 1996). F344 kidneys were transplanted orthotopically into bilaterally
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nephrectomised Lewis recipients. Control animals received low dose CsA for 10
days post-transplantation. In the study groups, a single injection of CTLA4Ig was
administered on day 2 post-transplant either alone or in addition to the 10 day CsA
regimen. Long-term graft survival was improved in both groups compared to
controls. Control animals developed progressive proteinuria and morphological
evidence of CAN by 16 to 24 weeks, whereas CTLA4Ig-treated animals did not.
These data suggest that T-cell recognition of alloantigen is an important early event
in the development ofCAN.
Other approaches
Angiopeptin is a long-acting cyclic octapeptide. It has pharmacological actions that
closely resemble those of the pituitary hormone somatostatin. In vitro studies have
demonstrated that it inhibits proliferation and migration of smooth muscle cells and
adhesion of mononuclear cells to vascular endothelium. The systemic administration
of angiopeptin reduces vascular myointimal thickening in both syngeneic and
allogeneic transplant models (Foegh et al 1995). There are no reliable data from
studies of angiopeptin in human renal transplant recipients with CAN. Human
cardiac allograft recipients who received subcutaneous angiopeptin for the first 14
days post-transplantation had less myointimal thickening (as measured by
intracoronary ultrasound) than a control group, but clinical outcome data were not
reported (Meisere^a/ 1995).
Many other immunological and non-immunological approaches to the treatment of
CAN have been considered. These include the use of platelet-activating-factor
antagonists (Hayry et al 1993), heparinoids (Aziz et al 1993), thromboxane receptor
antagonists, thromboxane synthase inhibitors and prostacyclin analogues (Teraoka et
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al 1987), fish oil supplements (Sweny 1993) and 1,25-dihydroxyvitamin D3
(Aschenbrenner et al 2001).
Platelet-activating factor (PAF) is a phospholipid mediator of inflammation that is
produced by inflammatory cells and endothelial cells. During acute allograft
rejection, PAF increases endothelial permeability and recruitment of inflammatory
cells within the graft (Renkonen et al 1999). It has been shown that a PAF antagonist
(WEB 2170) enhances the survival of renal allografts in dogs receiving either a
limited course of CsA or a reducing course ofCsA and AZA (Watson et al 1993). A
randomised, double-blind study of the PAF antagonist BN 52021 in de novo human
cadaveric renal transplant recipients (n = 29) showed a reduced incidence of delayed
graft function and acute rejection episodes (Grinyo et al 1994). Larger studies with a
longer period of follow-up are required.
Heparin inhibits smooth muscle cell migration and proliferation and can reduce the
accumulation of extracellular matrix that occurs after arterial injury. Aziz et al
studied low molecular weight heparin (LMWH) in combination with low dose CsA
in a rat heterotopic model of heart transplantation (Lewis-Brown Norway to Lewis).
Allograft survival improved significantly in comparison to rats receiving LMWH or
CsA alone. In addition, coronary disease affecting the graft was less severe and the
histological features of parenchymal rejection were less marked.
Endothelial cell injury induces platelet aggregation and release of thromboxane A2
(TXA2) and platelet-derived growth factor (PDGF) as well as activating the
coagulation cascade. PDGF and TXA2 are thought to play an important role in the
pathogenesis of vascular lesions in chronic vascular rejection (CVR) (Teraoka et al
1993). Studies of renal transplant recipients with chronic rejection have shown that
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thromboxane synthetase inhibitors and antiplatelet agents may reduce the rate of
disease progression, but patient numbers have been relatively small (Teraoka et al
1993, Teraoka et al 1996).
Aschenbrenner et al observed a slower progression of CAN in patients receiving
vitamin D supplements and proceeded to study control and 1,25-dihydroxy vitamin
D-treated rats using a Fisher to Lewis renal allograft model. They reported a
reduction in bioactive TGF-beta expression in the latter group but did not assess
differences in graft function or graft histology.
Sweny studied the effect of fish oil supplements in 14 patients with CAN. It is not
clear if biopsy evidence of CAN was obtained in all cases. The method of patient
selection is also unclear. Plasma creatinine values ranged from 168 umol/1 to 498
umol/1 with a group mean of 298 umol/1. Renal function was monitored during a 6
month run-in period (reference methods of measuring GFR were not used). MaxEPA
(containing polyunsatutated fatty acids and docosahexaenoic acid) was then
commenced at a dose of 0.2 ml/kg/day and continued for 6 months. The third phase
of the study was a 6 months observation period following cessation of MaxEPA.
During the treatment and follow-up periods, the rate of deterioration in graft function
was significantly reduced (p<0.05). Urinary protein excretion did not change but
there was a large reduction in serum triglyceride levels. Some patients complained of




Anticipation and prevention of CAN - identification
of predisposing factors
5.1 Concepts
5.1.1 TGF-beta 1 gene polymorphisms
As discussed in Section 4.4, expression of endogenous TGF-beta 1 in response to a
specific stimulus may vary between individuals as a result of polymorphisms in the
promoter, enhancer and leader sequences of the TGF-beta 1 gene. There is emerging
evidence of an association between some of these polymorphisms and the early
development ofCAN (Williams et al 2001).
We have examined further the clinical significance of genetic heterogeneity by
comparing the frequency distribution of TGF-beta 1 genotypes in renal transplant
recipients with stable long-term graft function and those with CAN. Confirmation
that genotypic differences are of prognostic importance would lead eventually to
tailoring of immunosuppressive regimens guided by the genetic profile of individual
transplant recipients for cytokines and other key components of the immune
response.
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5.1.2 Inter-individual variation in cyclosporin responsiveness using an
in vitro assay system
In clinical practice it is assumed that the concentration of CsA in the blood is an
adequate guide to the degree of CsA-mediated immunosuppressive activity in vivo.
We have reasoned that an assay of CsA responsiveness at the cellular level might
provide a more reliable measure of immunosuppressive activity, leading on to more
effective dosing of CsA for individual patients with the potential for an overall
improvement in long-term graft outcome.
Previous work with mixed lymphocyte cultures (MLCs, comprising a panel of
Epstein-Barr virus transformed, irradiated lymphoblastoid cells that express eight
different HLA-DR antigens) has shown that the sensitivity of recipient lymphocytes
to prednisolone and CsA in vitro predicts the outcome of renal transplantation
(Francis et al 1988; Francis et al 1991). Patients who were 'resistant' to these
immunosuppressive agents (defined arbitrarily as a less than 50% inhibition of the
MLC response) tended to have higher historical peak panel reactive antibody (PRA)
titres but were otherwise no different to 'sensitive' patients, even in respect of the
PRA immediately pre-transplant and the number of previous blood transfusions.
'Resistance' to either prednisolone or CsA was associated with an increased
incidence of steroid-resistant rejection and immunologic graft loss, and poorer graft
function during the first post-transplant year. Similar studies have been performed by
Takeuchi et al, using Con A as a mitogen (Takeuchi et al 1998). It was discovered
that interindividual variation in the concentration of CsA and tacrolimus that
produced 50% inhibition of in vitro lymphocyte blastogenesis (IC50) was much
greater in pre-transplant haemodialysis (HD) patients as compared to healthy
volunteers, although median values were similar. There was a significant correlation
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between sensitivities to CsA and tacrolimus in individual HD patients. Patients who
were 'sensitive' to immunosuppression had better graft function and graft survival as
compared to 'resistant' patients.
Other applications of in vitro testing for transplant recipients have been considered.
A bioassay for tacrolimus that is based on the inhibition of alloantigen-induced
proliferation of cloned alloreactive T cells has been presented as an alternative to
enzyme-linked immunoassay (ELISA) blood level monitoring (Zeevi et al 1991).
The ELISA may be misleading because it detects biologically inactive drug
metabolites as well as parent compound. Other work has shown that a positive
culture of lymphocytes from transplant biopsy specimens that are histologically
normal predicts a subsequent acute rejection episode and may therefore serve as a
guide to dosing of immunosuppressive agents in the early post-transplant period
(Weber et al 1989).
We have previously performed in vitro phytohaemagglutinin (PHA)-driven
lymphocyte function tests (using blood samples from healthy volunteers) in the
presence of CsA concentrations similar to those measured in the blood of CsA-
treated RTRs (Clark et al 2000). Abrogation of the PHA-driven response showed
wide inter-individual variability with peak inhibition of responsiveness being
obtained over a 20-fold concentration range. Moreover, in some cases the degree of
inhibition correlated poorly with CsA concentration. Even for individuals in whom a
concentration-dependent effect was obtained, maximal levels of inhibition were
always below 100% (interindividual range 69% - 96%), signifying that a proportion
of stimulated cells are refractory to inhibition by CsA in this assay.
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These data suggest that an assay which provides evidence of functional
immunosuppression may be useful in guiding the selection of individualised CsA
dosing regimens to maximise therapeutic benefit. Our initial approach to this
question has been to measure in vitro CsA responsiveness in renal transplant
recipients with and without CAN, using mononuclear cells extracted from peripheral
blood taken prior to the morning dose of CsA (when the blood CsA concentration is
at its lowest).
5.1.3 C2 monitoring and the implementation of a newly recommended
standard
As discussed in Section 4.1, acute renal transplant rejection may be the strongest risk
factor for the development of CAN (Hariharan et al 2002). The incidence of acute
rejection is likely to be reduced if more reliable ways of ensuring optimal
immunosuppression for individual patients are found. One disadvantage ofCsA is its
poor and variable absorption from the gastro-intestinal tract, leading to unpredictable
systemic exposure. The latter can be quantified in terms of the area under the time-
blood CsA concentration curve (AUC), which is a more reliable predictor of rejection
than trough (pre-dose) blood CsA levels (CO) (Lindholm et al 1993). Exact
measurement of AUC is too impractical for routine clinical use, but the more
consistent absorption characteristics of the Neoral® preparation of CsA has
encouraged the use of sparse (abbreviated) sampling techniques. For example,
Mahalati et al used blood CsA concentrations at 1 (CI), 2 (C2) and 3 (C3) hours
post-dose to calculate AUCO-4 (the systemic exposure to CsA during the first 4 hours
after dosing) in de novo renal transplant recipients. A low AUCO-4 at 3 days post-
transplant predicted the occurrence of an acute rejection episode (Mahalati et al
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2001). Barama et al have reported similar results using AUCO-12 calculated from CO,
C2 and C3 (Barama et al 2000). When combined with rapid and appropriate Neoral
dose adjustment, AUC monitoring is associated with very low rates of acute rejection
and CsA nephrotoxicity (Clase et al 2001).
In the above studies, the 2 hours post-dose CsA blood level (C2) was found to be the
most reliable single time-point predictor of AUCO-4. C2 may be even more
discriminating than AUC because of the importance of high CsA peak concentrations
(occurring approximately 2 hours after an oral dose of CsA) in suppressing T cell
responsiveness (Halloran 1998). A Cox regression analysis by Keown for the
International Neoral Renal Transplantation Study Group showed that freedom from
acute rejection depended on CsA absorption efficiency and C2 levels, with a
predicted rejection risk of 15-23% for good absorbers (>275 ug/l/mg/kg and C2
>1,500 ng/ml) versus 23-47% for poor absorbers (<200 ug/l/mg/kg and C2 <1,500
ng/ml) (Keown 2001). It has been recommended that a target C2 range of 1,350 -
2,050 ng/ml should be achieved within 5 days of transplantation and maintained
during the first post-transplant month, with lower targets for subsequent months
(i.e. 1,500 ng/ml in the second month, 1,200 ng/ml in the third and fourth months,
1,000 ng/ml in the fifth and sixth months and 800 ng/ml beyond 6 months). These
lower target levels are empirical and need to be tested in the clinical setting.
C2 monitoring has been applied successfully in the fields of heart and liver
transplantation (Levy 1998; Cantarovich et al 1999). A pilot safety analysis of its use
in renal transplant recipients has suggested that CsA dose adjustment based on C2
monitoring has no adverse impact on renal function, at least in the short term, despite
a probable net increase in CsA exposure (Cole et al 2001). A study by Britto et al has
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indicated that a lower C2 target may be appropriate for patients who receive antibody
therapy at induction (Britto et al 2001). The interim results of an international
multicentre prospective randomised study of C2 monitoring (M02ART) have been
encouraging both in terms of the safety and efficacy ofCsA dosing guided solely by
C2 values (Buchler et al 2002; Pfeffer ei al 2002).
We have sought to examine the association between C2 levels and early acute
rejection in our population of de novo renal transplant recipients. We have also
compared the sensitivity and specificity of C2 and CO for identifying patients who
develop early acute transplant rejection.
5.1.4 Variability of cyclosporin exposure and its relation to chronic
allograft nephropathy
The effect on CsA therapy on late renal allograft survival has been limited in
comparison to the substantial improvements in short-term outcome that were seen at
the time of its introduction in the early 1980s (Schweitzer et al 1991; Thorogood et
al 1992; Hariharan et al 2000). Large studies have found similar rates of graft loss
beyond the first post-transplant year for patients receiving prednisolone/CsA and
prednisolone/AZA regimens (Beveridge et al 1995; Vanrenterghem et al 1996). In
addition, it has been reported that chronic renal allograft dysfunction (CRAD)
secondary to CAN progresses at a similar rate in CsA and non-CsA treated renal
transplant recipients (Velosa et al 2001). These observations may be explained by
CsA having both beneficial and detrimental effects of CsA on transplant survival
(including perhaps an effect on patient mortality) that tend to balance out. It is also
conceivable that CsA fails to prevent CAN, a major cause of late graft failure for
which there are both immunologic and non-immunologic aetiologies (Lewis 1995).
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One of the difficulties in resolving these questions is that CAN and chronic CsA
nephrotoxicity share common histopathological features and may therefore be
indistinguishable. Furthermore, the two processes are not mutually exclusive and
often coexist. CsA may even contribute to the development and progression of CAN
(Mihatsch et al 1995).
Although treatment with CsA has had little effect on late allograft failure in renal
transplant populations, there is some evidence that for individualpatients the degree
and variability ofCsA exposure may be of prognostic importance.
Degree ofexposure
Several groups have reported an association between low cumulative CsA dose and
CAN (Schroeder et al 1995; Citterio et al 1998; Opelz 2001). Retrospective data
collected by the Collaborative Transplant Study Group indicate that graft survival is
also reduced in patients with a high CsA exposure, as measured by the weight-
adjusted CsA dose at one year post-transplant (Opelz 2001).
Variability ofexposure
In a longitudinal pharmacokinetic study of more than 200 patients by Kahan,
estimates of'area under the blood CsA concentration versus time curve' (AUC) were
derived using a multiple sampling technique (Kahan 1998). It was concluded that a
greater than 20% coefficient of variation ([SD/mean] x 100) of the dose-corrected,
time-averaged blood CsA concentration (Cav = AUC/t) was an independent risk
factor for the development ofCAN.
We have performed a case-control study to examine further the contribution of these
and other factors to the development ofCAN in renal transplant recipients receiving
follow-up at St James's University Hospital.
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5.2 Laboratory methods
Most of the laboratory work was performed in the Renal Research Laboratories at
Manchester Royal Infirmary and the Department of Transplant Immunology at St
James's University Hospital in collaboration with Dr PEC Brenchley and Dr B Clark.
5.2.1 Molecular studies
DNA extraction from peripheral blood cells
For each study participant a blood sample was collected into a potassium-EDTA tube
and the post-centrifugation cellular sediment retained and stored at -20 °C. In the
laboratory the sediment was allowed to thaw and the volume adjusted to
approximately 7.5 ml by adding phosphate buffer solution (PBS). Lysis Buffer 1
(LB1), consisting of 155mM ammonium chloride, lOmM potassium hydrogen
carbonate and ImM EDTA, was added to make a total volume of 25ml. After mixing
and slow rotation of the sample (approximately 30 minutes), the cell nuclei were
collected by centrifugation at 2,500 rpm for 10 minutes at room temperature with no
brake (IEC Centra 7). The supernatant was removed and 15 ml ofLB 1 added to wash
the pellet. The cycle was repeated and the pellet then vortexed prior to resuspension
in 6 ml of Lysis Buffer 2 (LB2), the latter comprising 2% SDS and 25 mM EDTA.
Following an incubation period of approximately 2 hours at room temperature,
precipitation of protein within the sample was achieved by addition of 2 ml of lOmM
ammonium acetate. After vortexing and centrifugation (2,500 rpm for 20 minutes at
room temperature, no brake), the supernatant layer was transferred into a fresh tube
containing propan-2-ol (isopropanolol) and DNA precipitation was encouraged by
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gentle inversion. Centrifugation (2,500 rpm at room temperature for 5 minutes, no
brake) was repeated and the supernatant was separated from the DNA pellet by
decanting and then micropipetting. The pellet was washed with 3 ml of 70% ethanol,
transferred to a microtube to air dry and then resuspended in 500 pi of distilled
water. The final DNA concentration of the sample was estimated by spectrometry
(260 nM) and a 500 ng/pl solution was prepared for subsequent use.
Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) is a laboratory technique that increases the number
of copies of a specific region ofDNA, thus providing a sufficient quantity ofDNA
for analysis. Essentially, a DNA preparation is heated to separate its paired double
helical strands (denaturation). Short 'primer' sequences of synthesised DNA are able
to bind to individual strands during cooling {annealing). Typically, the 'primers' are
an exact match for native DNA sequences flanking a genomic polymorphism that
lies in close proximity to the particular gene of interest. The next step is to extend the
annealed primer sequences using a DNA polymerase. The polymerase 'reads' the
'sentence' of an opposing native DNA strand and extends the annealed primer's
'sentence' by 'hooking' letters together in a complementary fashion {extension). The
steps of denaturation, annealing and extension are repeated several times (the DNA
polymerase is able to withstand high temperatures) to produce an exponential
increase in the number of copies ofDNA sequence.
Reaction mixtures were set up in 0.5 ml microfiige tubes. A negative control (water)






Reaction buffer x 10
Primers (x 2) 5 pM
DMSO (dimethylsulphoxide) 100 %
























Four polymorphisms in and around the TGF-beta 1 gene were examined in CsA-
treated adult renal transplant recipients with biopsy-proven CAN (n = 41) and
'controls' (CsA-treated patients with stable graft function for a minimum of four
years post-transplant and a serum creatinine of less than 200 umol/1, n = 57). These
are listed below together with a summary of the PCR protocol.
1) TGF-beta 1 -800 restriction fragment length polymorphism (RFLP)
Step Temperature Time
Initial denaturation 94 °C 3 min
Denaturation 94 °C 1 min
Annealing 60 °C 1 min
Extension 72 °C 1 min
Final extension 72 °C 5 min
(32 cycles, PCR product 388 base pairs)
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2) TGF-beta 1 -509 RFLP (only differences are shown)
Step Temperature Time
Annealing 55 °C 1 min
(32 cycles, PCR product 153 base pairs)
3) TGF-beta 1 codon 10 RFLP (only differences are shown)
Step Temperature Time
Annealing 55 °C 1 min
(35 cycles, PCR product 199 base pairs)
4) TGF-beta 1 codon 25 RFLP (only differences are shown)
Step Temperature Time
Annealing 62 °C 1 min
(32 cycles, PCR product 297 base pairs)
All of the above reactions were performed using a thermocycler (Perkin-Elmer Ltd,
Buckingham, UK). DNA primers were supplied by V H Bio (Newcastle, UK) and
deoxyribonucleotides by Gibco Life Technologies (Paisley, UK).
Restriction enzyme digests
The DNA sequence of the PCR products listed above varies between individuals.
Restriction enzymes are able to cleave or 'cut' DNA depending on the precise DNA
sequence around the cleavage site. Cutting produces shorter fragments ofDNA that
can be separated and subsequently identified by electrophoresis on an agarose gel.
The so-called restriction fragment length polymorphisms (RFLPs) that occur within
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bp = base pairs
The typical reaction mixture used for restriction enzyme digests was as follows:
Component Volume
Restriction enzyme buffer (10 x) 2 pi
Bovine Serum Albumin 0.1% w/v solution 0.2 pi
Restriction enzyme 0.2-0.5 pi at 10 U/pl
dFfeO to 5 pi
PCR product 15 pi
Allele Enzyme Temperature Digest Fragments
frequency
0.912/0.088 Tael 65 °C 3 hours 182 bp/ 206 bp
0.657/0.343 Bsu361 37 °C 3 hours 36 bp/117 bp
0.584/0.416 Not 1 37 °C 3 hours 17 bp/182 bp
0.918/0.082 Bgll 37 °C 3 hours 37 bp/260 bp
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Restriction enzyme preparations were supplied by Promega (Southampton, UK). The
DNA products of restriction digests were separated by agarose gel electrophoresis. A
standard 'ladder' comprising different lengths of DNA fragments was separated on
the same gel to aid characterisation of the digest products.
Genotype and allele frequencies in the two patient groups were compared using Chi
square.
5.2.2 Lymphocyte responsiveness to cyclosporin in vitro
PHA-driven lymphocyte responsiveness in vitro was measured in renal transplant
recipients with chronic renal allograft dysfunction secondary to CAN (n = 19) and
CsA-treated controls with stable graft function (serum creatinine < 200 umol/1) for a
minimum of 4 years post-transplant (n = 18). The assay comprised incubation of
peripheral blood mononuclear cells (obtained from pre-CsA dose blood samples)
with PHA (5 pg/ml) in the presence of added CsA (Neoral) at concentrations ranging
from 0 - 500 ng/ml. Cultures were pulsed with 3H thymidine at 72 hours and
harvested 18 hours later. The amount of radioactive signal at this time provided an
estimate of residual T cell activity (Rackbeta, Pharmacia, UK).
5.2.3 C2 monitoring and acute renal transplant rejection
For a period of 15 months starting in June 2000, trough (CO) and 2 hours post-dose
(C2) whole blood CsA concentrations were measured in samples obtained from
consecutive renal transplant recipients at or around the fifth post-operative day
(monoclonal antibody assay, Abbott Laboratories, Delkenheim, Germany). The
standard immunosuppressive regimen comprised prednisolone, AZA and CsA, but
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some patients (n = 18) received basiliximab (Simulect) and/ or MMF. In all patients,
CsA dose adjustments were made solely on the basis ofregular CO measurements.
We examined retrospectively the relationship between C2 levels at or around the
fifth post-operative day (day 4 or day 6 if there was no sample on day 5) and the
occurrence of acute rejection (AR, biopsy-proven or clinically suspected with
response to an increase in immunotherapy) within the first 20 days following
transplantation.
Two types of analysis were performed. In the first, a C2 value of > 1,500 ng/ml at or
around day 5 was taken as the standard. Patients were divided into 2 groups
according to whether or not this had been achieved. The proportions of patients in
each group who developed AR were compared using Chi-square. CO values for
patients with and without AR were compared using Mann-Whitney.
A Bayesian methodology was adopted in the second analysis, thus avoiding the need
for arbitrary grouping of patients to test a specific null hypothesis. Bayes' theorem
can be helpful in assessing the ability of a diagnostic test to predict a particular
clinical outcome in terms of its sensitivity, specificity, likelihood ratio, odds ratio and
predictive value. Some of this information is summarised graphically in a receiver
operating characteristics (ROC) curve. The ROC curve is a plot of sensitivity against
(1 - specificity) and is helpful in selecting a 'cut-off value that determines whether a
test result is positive or negative. In the context of this study, a Bayesian approach
allowed us to assess the usefulness of CO and C2 as predictors of early AR and to
evaluate de novo the most appropriate 'cut-off value for C2 in our study population.
Thus the sensitivity (the true positive rate) and specificity (the true negative rate) of
CO and C2 at or around day 5 for predicting AR within 20 days of transplantation
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were calculated for a range of'cut-off values (CO: 200 - 550 ng/ml, C2: 900 - 1,500
ng/ml). C2 concentrations of more than 1,500 ng/ml exceeded the upper limit of the
standard curve of the assay. These were reported as '> 1,500 ng/mf (double dilution
was not performed).
5.2.4 Variability of cyclosporin exposure
The renal unit electronic database at SJUH was interrogated to identify adult CsA-
treated renal transplant recipients with chronic progressive renal allograft
dysfunction (defined as a negatively sloping ROCT plot over a minimum of 6
months) secondary to biopsy-proven CAN (Banff category V, group A) and CsA-
treated controls with stable graft function for a minimum of four years post-
transplant and a serum creatinine of less than 200 umol/1 (group B). Exclusion
criteria included known non-compliance with immunosuppressive medication,
hepatobiliary disease and concomitant use of medications that interfere with CsA
metabolism. The following variables were recorded when available: age at
transplant, gender, years post-transplant, donor source, donor age, donor kidney
preservation time, HLA match, occurrence of delayed graft function,
immunosuppressive regimen, weight-adjusted CsA dose in the previous 12 months (6
categories; lowest category < 2mg/kg, highest category > 4mg/kg) and coefficient of
variation (CvarCo) of dose-adjusted CsA trough blood levels (C(/dose). Patients
transplanted before 1995 had received Sandimmun prior to Neoral® conversion. The
average duration of Sandimmun treatment was the same in both groups (median of
less than 1 year). CsA data from this period were not considered in view of the
likelihood that CvarCo would be different for the two CsA formulations. CsA data
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from the first 3 months post-transplant were also discounted because of uncertainty
as to the exact timing of the many CsA dose alterations that were made during this
period. CvarCowas calculated using the following formula:
CvarCo = (SD[Co/dose]/ mean[Co/dose]) x 100
The Chi square test was used to compare categorical variables in the two groups.
Continuous variables were compared using the Mann-Whitney and 2-tailed unpaired
t-tests as appropriate. In addition, a binary logistic regression analysis was performed
using a forward conditional sequential (stepwise) method of entering study variables
into a computerised model (SPSS software package version 9.0 for Windows 95,
Chicago, USA).
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5.3 Results and discussion
5.3.1 TGF-beta 1 gene polymorphisms
The TGF-beta 1 genotype of 41 patients with CAN and 57 CsA-treated controls with
stable graft function (as defined previously) was determined. Demographic data for
patients in the CAN group are summarised in Section 7.2. Data for 'control' patients
are summarised in Table 4 (group B, Section 5.3.4). Although the number of control
patients in each of the comparative studies that are described in this chapter differs
slightly (due to a failure to collect blood and/or urine samples in some cases), Table
8 can be regarded as a general summary of control group demographics.
Agrarose gel DNA electrophoresis was used to confirm DNA amplification by PCR
and identify DNA products of the restriction enzyme digests. A selection of gel
photographs is shown in Figures 3-10. Tables 1 and 2 summarise the allele and
genotype frequencies in the two study groups and in the general population
(Cambien et al 1996) for the four TGF-beta 1 gene polymorphisms (RFLPs) that are
listed in Section 5 .2.1. It can be seen that none of the inter-group differences in allele
or genotype frequency were statistically significant, suggesting that recipient TGF-
beta 1 gene polymorphisms do not predict the development ofCAN.
It is important to acknowledge the possibility of a type II statistical error in view of
the relatively small number ofpatients in the CAN group. Larger studies are required
to address this question.
There may be other possible explanations for our negative findings. Firstly, we
did not consider donor TGF-beta 1 genotype as this information was generally
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Figure 3. PCR product (400 bp) for the -800 TGF-
beta 1 gerie polymorphism
"
» o
Figure 4. Restriction enzyme digest for the -800 TGF-
beta 1 gene polymorphism
Lane 1 - DNA ladder, Lane 7 - GA heterozygote,
Lane 2 - GG homozygote, Lane 10 - AA homozygote
Figure 5. PCR product (153 bp) for the -509 TGF-
beta 1 gene polymorphism
1 234 56789 10 11
Figure 6. Restriction enzyme digest for the -509 TGF-
beta 1 gene polymorphism
Lane 1 - DNA ladder, Lane 3 - TT homozygote,
Lane 2 - CC homozygote, Lane 5 - CT heterozygote
Figure 7. PCR product (199 bp) for the codon
10TGF-beta 1 gene polymorphism
1 23456789 10 11
Figure 8. Restriction enzyme
beta 1 gene polymorphism
Lane 1 - DNA ladder,
Lane 2 - CC homozygote,
digest for the codon 10 TGF-
Lane 3 - CT heterozygote,
Lane 5 - TT homozygote
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Figure 9. PCR product (297 bp) for the codon
25 TGF-beta 1 gene polymorphism
Figure 10. Restriction enzyme digest for the codon 25
TGF-beta 1 gene polymorphism
Lane 1 - DNA ladder, Lane 6 - CC homozygote,
Lane 2 - TT homozygote, Lane 9 - CT heterozygote
unavailable. Evidence from previous studies suggests that donor genotype has an
effect on transplant outcome (Sankeran et al 1999). Secondly, there may have been a
failure to discriminate between chronic CsA nephrotoxicity and CAN on transplant
biopsy specimens (see Section 4.5), resulting in a heterogeneous study population.
Similarly, there may have been heterogeneity in the control group. The addition of
histopathological criteria to those specified in our study would reduce the likelihood
of including patients with subclinical CAN, however like most UK transplant centres
the Leeds unit does not routinely perform transplant biopsies in patients whose graft
function is stable.
Table 1. Allele frequencies for TGF-beta 1 gene RFLPs
RFLP Allele Patients with Patients with stable General
frequency CAN graft function population
-800 G 90% 93 % 92%
A 10% 7% 8%
-509 C 70% 66% 65 %
T 30% 34% 35%
Codon 10 C 44% 39% 38%
T 56% 61 % 62%
Codon 25 G 90% 95 % 91 %
C 10% 5 % 9%
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Table 2. Genotype frequencies for TGF-beta 1 gene RFLPs
RFLP Genotype Patients with Patients with stable General
frequency CAN graft function population
-800 GG 80% 88% 85 %
GA 20% 11 % 14%
AA 0 1 % 1 %
-509 CC 49% 45% 42%
CT 41 % 42% 47%
TT 10% 13 % 11 %
Codon 10 CC 24% 19% 17%
CT 39% 39% 47%
TT 37% 42% 36%
Codon 25 GG 83% 91 % 87%
GC 15 % 7% 12%
CC 2% 2% 1 %
Another possibility is that some of the patients in the study developed CAN as a
consequence of multiple factors including unrecognised poor compliance with
immunosuppressive medication, leading to an underestimation of the genetic
component. Consideration of a single cytokine genotype in isolation is undoubtedly
over-simplistic, but assessment of combinations of genotypes would require a
considerably larger study population. Finally, interindividual variation in TGF-beta 1
expression may be of lesser significance in chronic rejection as compared to acute
rejection (Sankeran et al 1999).
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5.3.2 Lymphocyte responsiveness to cyclosporin in vitro
The pre-dose concentrations of CsA in assay blood samples were similar in renal
transplant recipients with and without CAN. The mean percentage reduction in
lymphocyte responsiveness (LR) relative to the culture with no added CsA was
greater in patients with CAN at all CsA concentrations, although the difference was
not statistically significant (p = 0.12, Figure 11).
The similarity of the results in the two groups is clearly not what would be expected
from a test that is capable of predicting long-term renal transplant outcome. This may
be taken as further evidence of the importance of wow-immunological factors in the
development ofCAN. It could be also that a test based on mitogenic stimuli such as
PHA is less informative than a test based on a donor-specific cognate alloantigenic
stimulus.
There are other ways of interpreting the data. The larger reduction in LR seen in
patients with CAN may indicate that they are more sensitive to other (non-
immunological) effects ofCsA, including perhaps programmed cell death (apoptosis)
and tissue fibrosis (both of which are thought to be relevant to the development of
CAN). Alternatively, differences in LR reduction could be explained by there being a
CsA-mediated immunosuppressive activity in vivo which is further from its
maximum (i.e. there is greater potential for reducing LR in vitro) in patients who
develop CAN.
The best way of exploring these concepts further is to perform a large, prospective
pre-transplant study of in vitro sensitivity to all of the immunosuppressive agents that
are in common use, employing both mitogenic and cognate alloantigenic stimuli.
This would make it possible to measure absolute reductions in LR rather than change
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Figure11.Invit olymphocyteresponsivenessi atienw tha d withoutCAN Cyclosporinoncentration(ng/ml)
o
On
in LR relative to a pre-established in vivo CsA activity (although the effect of the
latter was minimised in this study by using pre-CsA dose blood samples).
5.3.3 C2 monitoring and acute transplant rejection
88 adult patients were transplanted and received CsA-based immunosuppression
during the period of study. C2 data were available in all but 12 patients, none of
whom developed AR. The median C2 value for the 11 patients who developed AR
was 1,192 (interquartile range 1,008 - 1,286) ng/ml. The median CO value for the
same 11 patients was 389 (interquartile range 365 - 421) ng/ml, compared to 418
(interquartile range 311 - 469) ng/ml for those without AR (p = 0.8).
In the first analysis, a C2 measurement of > 1,500 ng/ml at or around day 5 was
taken as the standard. Patients were divided into 2 groups according to whether or
not this had been achieved.
Of the 25 patients with C2 > 1,500 ng/ml (group A), only one developed AR. 5
patients in group A had received basiliximab (Simulect), 2 in combination with
MMF. Another patient was taking MMF in place ofAZA. Of the 51 patients with C2
< 1,500 ng/ml (group B), 10 developed AR. 9 of the 10 had received standard triple
therapy (1 received MMF in place of AZA). Of the 41 patients in group B who did
not develop AR, 5 had received basiliximab and 6 were taking MMF instead of
AZA. This clinically significant difference in the frequency ofAR between groups A
and B did not reach statistical significance (Chi square, p = 0.07).
The Bayesian analysis allowed us to compare the usefulness of CO and C2 as
predictors of early AR and to evaluate de novo the most appropriate 'cut-off value
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Table 3. Summary statistics for various C2 'cut-off values
C2 'cut¬ sensitivity 1 - positive positive PPV - prior
off value specificity likelihood predictive probability
(ng/mL) ratio value of rejection
(PLR1) (PPV2) (11/76)
<900 0.18 0.15 1.20 0.55 0.40
< 1000 0.27 0.21 1.29 0.56 0.42
< 1100 0.36 0.26 1.38 0.58 0.44
< 1200 0.55 0.31 1.77 0.64 0.49
< 1300 0.73 0.44 1.66 0.62 0.48
< 1400 0.91 0.52 1.75 0.64 0.49
< 1500 0.91 0.61 1.49 0.60 0.45
1 the likelihood of a C2 value below 'cut-off in patients who develop acute rejection
compared to patients who do not develop acute rejection
2 the probability of acute rejection in patients with a C2 value below 'cut-off
for C2 in our study population. Receiver operating characteristic (ROC) plots for CO
and C2 are shown in Figure 12.
It is clear that C2 has greater specificity for early AR than CO at all levels of
sensitivity and is therefore the more discriminating of the two measurements. The
positive predictive value (PPV) of C2 for AR at various 'cut-off levels in our own
population of transplant recipients is shown in Table 3. The PPV of a test will of
course vary according to the incidence ofAR in the population that is studied.
This analysis of C2 data collected at or around day 5 post-transplant appears to
support the notion that higher peak blood levels of CsA are associated with a lower
incidence of early AR, although the sample size is too small to demonstrate statistical
significance and we did not examine rigorously the effect of factors other than CsA
exposure that may have influenced graft outcome. There were no major differences
in terms of immunosuppressive therapy between the 2 groups. As C2 is a more
specific indicator of suboptimal CsA dosing than CO at any chosen level of
sensitivity, the use of a CsA dosing algorithm based on C2 values would be expected
to result in fewer unnecessary dose increases during the early post-transplant period
as compared to an algorithm based on CO values.
A pharmacokinetic model for CsA has been developed in conjunction with the
Department ofBiomedical Sciences at Leeds University, forming the basis for an 'in
house' CsA dosing algorithm that is to be applied in the clinical setting.
It remains to be seen if C2 monitoring in combination with rapid and appropriate
CsA dose adjustment will be effective in reducing the incidence of early, acute renal
transplant rejection. There are resource and logistic implications of a change to C2
monitoring which include additional staffing to ensure accurate timing of
venepuncture and increased laboratory costs, and these must be balanced against
patient benefit and financial savings that may result from a lower incidence of
transplant rejection. In addition, there are currently no prospective data to confirm
the findings of retrospective studies that prevention of early acute renal transplant
rejection reduces significantly the likelihood of subsequent CAN.
5.3.4 Variability of cyclosporin exposure
Of the 105 patients who met the study inclusion criteria, 3 were excluded because of
documented poor compliance with immunosuppressive medication, leaving a study
population of 102 patients.
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Table 4. Patient demographics according to study group





Age (years) [102] 31.1 ± 13.3 1 42.0 ± 16.3 <0.001
Male:female ratio [102] 1.34 1.39 NS
Time post-transplant (years) [102] 6 (4-8.5) 2 6(5-9) NS
HLA mismatches (A/B/DR loci) [94] 0.8/0.8/0.5 0.7/1.1/0.6 NS
Weight-adjusted CsA dose
(mg/kg/day) [102]
4.3 ± 1.6 3.0± 1.6 <0.02
Cold ischaemia time (hours) [83] 15.6 ±9.1 16.2 ±5.5 NS
Donor age (years) [94] 37.9 ± 17.6 35.4 ± 16.5 NS
Donor source (% living donor) [102] 12 4 NS
Delayed graft function (%) [95] 12 17 NS
CvarCo (%) [102] 26.3 ±9.4 21.1 ±7.6 <0.01
Immunosuppressive regimen (%) [102]
Pred-Aza-CsA 86 78 NS
Pred-CsA 11 14
CsA 3 8
Serum creatinine 3 (umol/1) [102] 230 ± 73 127 ±25 <0.001
C04(ng/ml) [102] 138 ±45 143 ± 46 NS
1
mean ± SD
2 median (interquartile range)
3
as of June 2001, or the time of immunosuppression conversion if this was sooner
(group A patients)
4
trough blood level ofCsA
ill
Data are summarised by patient group in Table 4. The median number of Co values
per patient was 36 (IQR 27.5 - 43) in RTRs with CAN (group A) compared to 26
(IQR 22 - 33.5) in RTRs with stable graft function (group B, p = 0.01). The median
number of Co values per patient per annum was 6.7 (4.9 - 8.7) in group A and 4.8
(3.7 - 7.3) in group B (p = 0.005). Recipient age, CvarCo and weight-adjusted CsA
dose for the preceding 12 months were found to be significantly different in the two
groups. As the latter variable is a potentially inaccurate method of standardising CsA
dose, an inter-group comparison of body weight was made. The difference was
insignificant (p = 0.36), suggesting that body weight was not a confounding factor in
the analysis.
Low recipient age and a high CvarCo were the only significant independent
predictors of CAN in the multivariate analysis. The regression model coefficients for
the two variables are shown in Table 5.
Table 5. Results of the binary logistic regression analysis
Variable Coefficient 95% Confidence Interval P value
Recipient age -0.07 -0.03 to -0.11 <0.001
CvarCo 0.09 0.02 to 0.16 <0.02
This case-control study has demonstrated that there is an increased likelihood of
CAN in younger renal transplant recipients and those with variable CsA exposure (as
indicated by a high CvarCo), although the difference in mean CvarCo values for the
two study groups was small. There was a trend for patients with CAN to be receiving
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a higher weight-adjusted maintenance dose of CsA but this was not a significant
predictive variable in the multivariate regression analysis (p = 0.07).
Recipient age has been found to predict immunologic graft survival (graft loss
secondary to acute or chronic rejection, excluding all other causes including death
with a functioning transplant) in previous studies (Pirsch et al 1996; Bradley 2000).
The explanation for this is unclear. It may be that younger recipients maintain a
higher level of immunoresponsiveness following renal transplantation.
Although a high CvarCo predicts the development of CAN it is apparent that CsA
exposure varies considerably even in some patients with apparently stable transplant
function. This has been attributed to unpredictable absorption of CsA from the
gastro-intestinal tract (Lindholm et al 1993) but unrecognised poor compliance with
immunosuppressive medication is likely to be another important factor.
As previously discussed, Kahan et al used a measure of CsA exposure (Cav) that is
more accurate than Co but less suitable for routine clinical use. Recent studies have
shown that 'sparse sample' methods (notably measurement of C2, the 2-hour post-
dose CsA concentration) are reliable alternatives to Cav but there remain practical
difficulties for outpatient populations (Belitsky et al 2000).
The receiver operating characteristics (ROC) curve in Figure 13 shows the sensitivity
and specificity of a range of 'cut-off values of CvarCo for predicting the
development ofCAN in our study population. As a true impression of the variability
ofCsA exposure requires several Co measurements, the reliability ofCvarCo is likely
to increase with time post-transplant.
The trend towards a higher weight-adjusted CsA dose in patients with a diagnosis of

















is a difficulty in discriminating between CAN and chronic CsA toxicity. The
histopathological features of chronic CsA toxicity in renal allografts include striped
tubulointerstitial fibrosis, tubular atrophy and nodular hyperplasia of afferent
arterioles (Feutren et al 1992) but only non-specific features are present in some
cases. Klintmalm et al compared renal biopsy features in both CsA-treated and non-
CsA-treated recipients and found more extensive interstitial fibrosis and tubular
atrophy in the former group (Klintmalm et al 1984). There was a positive correlation
between the severity of the histopathological features and both CsA trough levels and
the cumulative prescribed CsA dose during the first 6 post-transplant months.
An alternative explanation for the association between CsA exposure and CAN seen
in this study is that CsA has effects other than an alteration in renal hemodynamics
that are central to the development of CAN. For example, even small doses of CsA
promote the synthesis in vitro of extracellular matrix components such as collagen
type III (Ghiggeri et al 1994; Oleggini el al 2000). CsA may also stimulate
production of TGF-beta 1, a cytokine that has both immunosuppresive and fibrogenic
properties (Shihab et al 1996). Kahan has reported a positive correlation between
serial C2 values and the development ofCAN within 3 years post-transplant (Kahan
2002).
The similarity of mean serum Co concentrations in the two study groups (138 + 45
ng/ml in group A vs 143 + 46 ng/mL in group B, p = NS) presents a third possible
explanation, namely that patients who develop CAN may be poorer absorbers ofCsA
with lower peak blood CsA concentrations. This could be explored by looking at C2
data.
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In summary, our data suggest that renal transplant recipients with highly variable
CsA exposure have an increased likelihood of developing CAN. Investigation of
such patients may allow differentiation between true intrinsic variability of CsA
absorption and other factors (previously unrecognised poor compliance with CsA
treatment, irregular medication/foods that interfere with CsA metabolism) and so
lead on to appropriate interventions.
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Non-invasive methods of detecting early CAN
6.1 Concepts
6.1.1 TGF-beta 1 expression in plasma and urine
TGF-beta 1 expression was measured in plasma and urine samples that were
provided by patients who participated in the immunosuppression conversion study.
The analysis was undertaken for two main reasons. Firstly, there is some doubt as to
the activity ofTGF-beta 1 at different stages in the development ofCAN as there are
no prospective longitudinal studies. One group has reported that urinary excretion of
TGF-beta 1 increases in proportion to the severity of CAN (Boratynska 1999).
Secondly, as discussed in Section 4.4, some authors have claimed that TGF-beta 1
expression is promoted by CsA. It would therefore be of interest to study the pattern
of TGF-beta 1 expression in CsA-treated patients with CAN who undergo
immunosuppression conversion (CsA to tacrolimus/ addition ofMMF with CsA dose
reduction).
6.1.2 NAG expression in urine
The lysosomal enzyme N-acetyl P-D glucosaminidase (NAG) is synthesised by
proximal renal tubular epithelial cells. If these cells become damaged, NAG leaks
into the tubular lumen and is detectable in the urine. It has been shown that low
urinary NAG excretion during the immediate post-transplant period predicts
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satisfactory early graft function (Matteucci et al 1998) and a rise in NAG excretion
typically precedes a rise in serum creatinine. Kontanko et al studied NAG excretion
between days 7 and 28 post-transplant in 33 renal allograft recipients who had an
uncomplicated first post-operative month (Kotanko et al 1996). Data were evaluated
in relation to graft status after 4 and 6 years. A Cox proportional hazards model
identified low urinary NAG excretion (adjusted according to the urine creatinine
concentration) as an independent risk factor for graft loss. This finding is difficult to
explain. One theory is that low NAG excretion reflects a low size of graft (the source
ofNAG) to recipient body mass (a determinant of urinary creatinine excretion) ratio,
which is itself known to be associated with poorer long-term graft survival. Other
work suggests that NAG excretion is dependent on CsA dose (Marchewka et al
1999).
It is not clear whether urinary excretion of NAG is raised in CAN. A study by
Wellwood el al examined urine NAG excretion in 181 renal allograft recipients over
a period of 15 months (Wellwood et al 1978). Their finding of high levels ofNAG
excretion immediately post-transplant with a subsequent reduction in uncomplicated
cases is consistent with other studies, but it was also noted that excretion increased in
association with chronic rejection, hypotension, renal artery stenosis, renal vein
thrombosis and the administration ofgentamicin.
We have tested the following hypotheses :-
(1) The magnitude ofurine NAG excretion is proportional to the severity ofCAN
(2) A reduction in urine NAG excretion is an early and reliable non-invasive marker
of response to a therapeutic intervention for CAN (immunosuppression conversion in
this study).
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6.1.3 Serum cystatin C and GFR prediction equations based on serum
creatinine
The ability to detect chronic renal allograft dysfunction at an early stage in its
development is important in terms of establishing a diagnosis and initiating
appropriate treatment. Serum creatinine is used as a measure of renal function in
clinical practice, but there are significant disadvantages in terms of its poor
sensitivity and the effect of non-renal factors on both the blood concentration of
creatinine and the performance of creatinine assays (Perrone et al 1992). Creatinine
clearance may be calculated from measurements of creatinine in blood and urine.
Such estimations are reported to be inaccurate, especially if supervision of timed
urine collections is inadequate. Renal tubular secretion of creatinine leads to a
significant overestimation of GFR when excretory function is impaired such as in
CAN.
More accurate methods for determining GFR have been described, including inulin
clearance and clearances of chelated isotopes such as [51Cr] EDTA and [125I]
iothalamate. These methods involve the exposure of patients to ionising radiation.
They are time-consuming, laborious and expensive and are not used routinely in
clinical practice.
Serum cystatin C
There has been interest in finding simple methods of measuring renal function that
are superior to serum creatinine. Cystatin C is a non-glycosylated 13 kD basic
protein that inhibits cysteine protease. It is synthesised by all nucleated cells (unlike
creatinine) and its rate of production is not influenced by inflammatory conditions
(unlike beta-2 microglobulin). Its concentration in the serum is determined mainly by
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the glomerular filtration rate (GFR) (Simonsen et al 1985; Grubb 1992). Different
assay methods for measuring cystatin C have been described, including enzyme
amplified single radial immunodiffusion (SRID), ELISA and latex particle enhanced
immunoturbidometry (PENIA). The latter is an automated technique and can
therefore be used in clinical practice. There is convincing evidence that serum
cystatin C is a more sensitive endogenous marker of mild renal dysfunction than
serum creatinine (Figure 14, Newman et al 1995).
Previous work has suggested that serum cystatin C measurements in paediatric
transplant recipients tend to be higher than those obtained in children with native
renal dysfunction at all levels of renal clearance (Bokenkamp et al 1999). This may
be explained by the presence of factors that interfere with the cystatin C assay, either
directly or via metabolic changes induced by immunosuppressive therapy. Other
possibilities include tubulo-interstitial damage, leading to a back-leak of intact
cystatin C from renal tubules into the circulation, and impaired filtration of cystatin
C resulting from increased protein binding within the circulation. There is no
experimental evidence to support any of these theories at present, except for a recent
study by Risch et al that reported an association between higher serum cystatin C
concentrations and glucocorticoid therapy in renal transplant recipients (Risch et al
2001). The mechanism underlying this association (e.g. change in the rate of cystatin
C production and release from cells, interference with cystatin C assays) has not yet
been elucidated.
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A study of 33 adult renal transplant recipients with stable graft function examined
the relationship between GFR estimations obtained from [123I] iothalamate clearance,
creatinine clearance (using the Cockroft-Gault and Walser equations) and serum
cystatin C (Risch et al 1999). In terms of positive predictive value and positive
likelihood ratio (taking a GFR of less than 60 ml/min/1.73m2 as abnormal), serum
cystatin C was of similar diagnostic value to calculated creatinine clearance.
Tian et al detected cystatin C in the urine of patients with native renal impairment
(Tian et al 1997). The fractional clearance of cystatin C varied inversely with
creatinine clearance. It is not clear whether this finding reflects variation in the
severity of proximal tubular damage or simply a delivery rate of cystatin C to intact
nephron units that exceeds tubular reabsorption capacity.
We have sought to assess the correlation between serum cystatin C (measured using
a particle-enhanced nephelometry technique (PENIA)), GFR and serum creatinine
measurements in an adult population of renal transplant recipients with CAN. A
strong correlation with GFR would establish the validity of cystatin C measurements
in this setting.
GFR prediction formulae
An alternative to measuring GFR by a reference method is to produce reliable
estimates of GFR using formulae that are based on biochemical, demographic and
anthropometric data. We have compared GFR estimates from such formulae with
radioisotope GFR measurements in a population of renal transplant recipients with
impaired graft function secondary to CAN. The formulae are summarised below:
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Jelliffe equation (Jelliffe 1973)
Creatinine clearance (males) = 98-16 [(age in years - 20) 4- 20] h- plasma creatinine
(umol/1)
(multiply value by 0.9 for females)
Cockroft-Gault equation (Cockroft et al 1976)
Creatinine clearance (males) = 1.2 x [(140 - age in years) x body weight (kg)] -s-
serum creatinine (umol/1)
(multiply value by 0.85 for females)
Nankivell 'B' equation (Nankivell et al 1995)
GFR = [6.7 -s- serum creatinine (mmol/1)] + [body weight (kg) -s- 4] - [urea (mmol/1) h-
2] - [100 -r- height2 (m2)] + [35 for males, 25 for females]
Walser equation (Walser et al 1993)
GFR x 3 -f- height2 (m2) = a + [b x serum creatinine (mg/dl)] + [c x age in years] + [d
x weight in kg]
males females
a = -6.66 -4.81
b = +7.57 +6.05
c = -0.103 -0.08
d = +0.096 +0.08
MDRD (Modified Diet in Renal Disease) equation (Levey et al 1999)
GFR = 170 x [PCr] "°'999 x [age] "0176 x [0.762 if patient female] x [1.180 if patient
black] x [SUN] -0170 x [Alb] ^318
PCr = serum creatinine concentration (mg/dl), SUN = serum urea nitrogen
concentration (mg/dl), Alb = serum albumin concentration (g/dl)
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Bokenkamp formula for cystatin C (Bokenkamp et al 1999)
GFRcys = [137 h- cystatin C (mg/1)] - 20.4
The latter four formulae predict GFR rather than creatinine clearance, which exceeds
the GFR measurement in patients with renal dysfunction. The MDRD formula has
been derived and validated using [125I] iothalamate as the reference method in large
cohorts of patients with native renal impairment ('training sample', n = 1,070;
'validation sample', n = 558, mean GFR 40 + 20 ml/min/1.73m2) (Levey et al 1999).
A preliminary study by Bedros et al has suggested that the formula provides reliable
estimates of graft function in renal transplant recipients (Bedros et al 1998). As the
only measured inputs required for the formula are results of routine laboratory tests,
GFR values can be generated by a computerised reporting system with access to
these data. The Walserformula was derived from patients with a low renal clearance
and has been shown previously to provide a reliable estimate of GFR in renal
allograft recipients (Walser et al 1993; Goerdt et al 1997). The Nankivell formula
was derived from a population of renal transplant recipients (Nankivell et al 1995).
The Bokenkamp formula was derived from children (mean age 11.2 + 4.8 years) with
a wide range of renal disease. The concentration of cystatin C in the serum is
reported to be independent of lean body mass, body surface area (hence the absence
of anthropometric terms in the formula) and age beyond one year.
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6.2 Laboratory methods
Most of the laboratory work was performed in the Renal Research Laboratories at
Manchester Royal Infirmary and the Department of Transplant Immunology at St
James's University Hospital in collaboration with Dr PEC Brenchley and Dr B Clark.
6.2.1 Enzyme-linked immunosorbent assay (ELISA) for TGF-beta 1 in
plasma and urine samples
Blood samples were collected into EDTA tubes and centrifuged at 3,000 rpm for 10
minutes at 4 °C with medium brake. 1 ml aliquots of plasma were transferred to
cryovials and stored in cryoboxes at -70 °C. Urine samples were collected into plain
Universal tubes and then transferred to cryovials for storage alongside the plasma
samples.
The ELISA protocol has been described elsewhere (Coupes et al 1994). Essentially,
the wells of a MicroFLUOR 'W' plate (Dynatech Technologies, Chantilly, USA)
were coated with 100 pi of a solution comprising 2.5 pg/ml mouse monoclonal
antibody to TGF-beta 1, 2 and 3 (Genzyme, Cambridge, USA) in coating buffer and
left overnight in a damp box at 4 °C.
The coating solution was then removed by flicking and the wells were 'blocked' with
150 pi of ELISA buffer (EB, a 0.1% w/v solution of bovine serum albumin (BSA,
First Link Ltd, Brierley Hill, UK) in PBS). Meanwhile, a standard curve of
recombinant human TGF-beta 1 (rhTGF-beta 1, R and D Systems, Abingdon, UK)
solutions was produced by double dilution from 5 ng/ml to 0.075 ng/ml. A dilution
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of the internal standard (NIBSAC TGF-beta 1, 1.6 ng/ml, National Institute of
Biostandards and Controls, UK) was also prepared.
After completion of the blocking step (1-2 hours), the plate was washed 5 times in
washing buffer (PBS and polyoxyethylene sorbitan monolaurate (Tween)). 100 pi of
the standards and NIBSAC TGF-beta 1 were pipetted into wells in duplicate.
Samples were also pipetted in duplicate and diluted to a volume of 100 pi with BSA
(plasma 1:4, urine 1:1). The plate was then left overnight in a damp box at 4°C.
After further washing, 100 pi aliquots of 2 pg/ml chicken anti-TGF-beta 1 (R & D
Systems) were applied to each well. The plate was then left for 2 hours at room
temperature on a plate shaker. Another washing step was performed and 100 pi of
1:100,000 peroxidase-conjugated donkey anti-chicken antibody (Jackson
Immunoresearch Laboratories, Luton, UK) were added to each well. After incubation
at room temperature for 1 hour, washing was repeated and 100 pi of
chemiluminescent signal substrate comprising equal volumes of peroxide and
luminol enhancer solutions (SuperSignal® West Pico, Pierce, USA) were applied to
each well. The plate was shaken for 2 minutes prior to reading of signal with a
luminometer (Microlumat, EG & G Wallace, Milton Keynes, UK). The results were
analysed using Mikrotek software.
The assay is capable of measuring TGF-beta 1 concentrations in excess of 75 pg/ml
with a working range of up to 25,000 pg/ml. The intra-assay coefficient of variation
is approximately 5%. The detection antibody has been shown to be specific for TGF-
beta 1. Neither freeze thawing or prolonged incubation of blood or plasma at room
temperature alters the detection of TGF-beta 1. There is no detectable TGF-beta 1 in
normal plasma.
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Measurements of TGF-beta 1 in urine were standardised by calculating TGF-beta 1:
urine creatinine ratios. Urine creatinine was measured using an 'in-house' multiwell
plate version of the Sigma creatinine assay (Sigma Diagnostics, Gillingham, UK).
Essentially, urine samples were diluted to a 1 in 10 concentration using distilled
water. Sequential dilutions of the Sigma Standard Creatinine Solution (15 mg/dl)
were prepared. 20 p.1 aliquots of the samples and the creatinine dilutions were
pipetted onto an assay plate. 200 pi of an alkaline picrate solution were added and
mixed on a plate shaker. The absorbance for each well was read at a wavelength of
490 nm. 7 pi of Sigma Acid Reagent was then added to all wells and the plate was
read at 490 nm after 5 minutes. The creatinine concentration of each sample was
calculated from the difference between the two readings.
Plasma and urine samples were collected from patients with CAN who were
participating in the immunosuppression conversion study (Chapter 7) on a monthly
basis. Samples from CsA-treated 'control' patients with stable long-term graft
function (serum creatinine < 200 umol/1) for a minimum of 4 years post-transplant
were also collected. Both the study and control patients were identified by
interrogation of the electronic record of patients receiving transplant follow-up care
at St James's University Hospital in Leeds. Differences between groups were
compared using Mann Whitney and the Kruskal-Wallis test for independent samples.
6.2.2 Measurement of NAG in urine
Morning urine samples were obtained from patients with CAN (n = 25, mean serum
creatinine 225 umol/1) and a number of CsA-treated controls with stable graft
function for a minimum of 4 years post-transplant and a serum creatinine of < 200
umol/1 (n = 58, mean serum creatinine 125 umol/1). Samples were collected into plain
Universal containers and transferred to the Department of Clinical Pathology at St
James's University Hospital, where the urine was pipetted into polypropylene tubes
and stored at -20 °C pending analysis. For patients with CAN, samples were
collected weekly for one month and then monthly for 6 months.
A colorimetric assay was used to quantify the amount ofNAG in all urine samples
(PPR Diagnostics Ltd, London, UK). The test is based on NAG-induced hydrolysis
of a substrate releasing a phenolic compound that, in the presence of buffer salts,
produces a red colour in proportion to the degree of hydrolysis. The intensity of the
coloration can be read using a spectrophotometer set to a wavelength of 505 nm. The
assay has been described in more detail elsewhere (Yuen et al 1984). NAG
measurements were adjusted according to the urine creatinine concentration.
The data were analysed in relation to two key questions. Firstly, baseline
measurements of patients with CAN were compared with those of CsA-treated
'control' patients with stable long-term graft function for a minimum of4 years post-
transplant to find evidence of an association between urinary NAG excretion and
CAN. Secondly, the effect on NAG excretion of immunosuppression conversion
(CsA to tacrolimus/ azathioprine to MMF with CsA dose reduction/ 'no change'
controls) and intraindividual variation in transplant function (measured using a
reference radioisotopic method) was explored.
6.2.3 Estimates of renal function - GFR, serum cystatin C and GFR
prediction equations based on serum creatinine and serum cystatin C
99mTcDTPA-GFR was measured in 33 CsA-treated patients (10 female, age range
20 to 67 years, body mass index 18 to 32 kg/m2) with CAN. Calculated GFR values
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were obtained from the MDRD, Jelliffe, Cockcroft and Gault, Nankivell 'B', Walser
and Bokenkamp formulae using data collected on the day of the isotope study. These
were compared with 99mTcDTPA-GFR measurements (corrected for body surface
area using the DuBois equation) by calculating bias (the median difference between
calculated GFR and 99mTcDTPA GFR) and scatter (the median absolute difference
between calculated GFR and 99mTcDTPA GFR).
Serum cystatin C was measured using PENIA (Dade Behring, Marburg, Germany).
The principle of the method is that polystyrene particles coated with antibodies to
cystatin C agglutinate when mixed with samples containing cystatin C. Agglutination
alters the intensity of scattered light within a nephelometer. The concentration of
cystatin C in a sample is derived by comparison with nephelometer readings obtained
using standard cystatin C solutions of known concentration. The assay has been
described in more detail elsewhere (Finney et al 1997). Tests of correlation between
1/cystatin C, 1/serum creatinine and 99mTcDTPA-GFR data were performed at the
start of the study and after 6 months.
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6.3 Results and discussion
6.3.1 TGF-beta 1 expression in plasma and urine
There was no detectable TGF-beta 1 expression in plasma samples from CAN
patients and controls with the exception of a single patient in the CAN group. He
subsequently underwent immunosuppression conversion (MMF/ reduced dose CsA,
see Chapter 7) and there was a trend of decreasing TGF-beta 1 expression during the
period of follow-up.
Figure 15 shows the distribution of adjusted urine TGF-beta 1 concentrations in the
two study groups. Interestingly, urine TGF-beta 1 excretion was significantly higher
in controls as compared to patients with CAN.
Box plots of urine TGF-beta 1 data that were collected over a period of 6 months
from patients with CAN are shown according to their randomised treatment
intervention (MMF and reduced dose CsA/ tacrolimus in place of CsA/ continuation
of CsA-based immunosuppression) in Figure 16. The boxes indicate the upper and
lower quartiles and the central line is the median value. The points at the end of the
'whiskers' are the 2.5% and 97.5% values. Median values of urine TGF-beta 1 were
fairly constant over time in the control group of patients. It is perhaps surprising in
view of the known effect of CsA on TGF-beta 1 expression that urine TGF-beta 1
values did not decrease in patients who underwent immunosuppression conversion.
There was no significant difference in urine TGF-beta 1 values between treatment
groups at either the start or the finish of the study (Table 6).
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Table 6. Urine TGF-beta 1 measurements in patients with CAN according to
immunosuppressive regimen
MMF/ reduced Tacrolimus CsA P value
dose CsA (no change) (Kruskal-
Wallis)
Start of study 37 (25-76)1-* 48 (0-97) 42 (27-66) NS
At 6 months 41 (16-62) 114(72-145) 47 (24-333) NS
1
expressed as a TGF-beta (pg/ml) to creatinine (mg/dl) ratio
2 median (interquartile range)
Figure 17 is a plot of urine TGF-beta 1 concentration against 99mTcDTPA-GFR in
patients with CAN at the start of the study. It can be seen that the correlation between
the two measurements is poor, indicating that TGF-beta 1 expression is not a reliable
marker of the chronicity and severity ofCAN.
Figure 18 is a plot of urine TGF-beta 1 concentration against urine protein creatinine
index (PCI) at the start of the study and shows that urine TGF-beta 1 excretion
cannot be estimated reliably from a urine test that is used routinely in clinical
practice.
In summary, these data suggest that TGF-beta 1 excretion in the urine is not a useful
marker of CAN. A fundamental criticism of urine TGF-beta 1 as a marker of graft
injury is that it may not reflect accurately the degree of activity of TGF-beta 1 within
the graft. The latter can be studied using in situ hybridisation staining of transplant
biopsy material but sampling error reduces the validity of this approach. Correction
of urine TGF-beta 1 measurements based on the urine creatinine concentration may
be flawed, as the latter depends on several factors other than the volume of urine
output (such as diet, the size of the body creatinine pool and the extent of creatinine
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creatinine secretion by the renal tubules). However, similar results to those presented
above were obtained using uncorrected TGF-beta 1 values. It may be that a reduction
in nephron mass influences TGF-beta 1 excretion, although in our study there was no
correlation between urine TGF-beta 1 and GFR in patients with CAN. Prospective
cohort studies are underway in Manchester and these may provide more information
about patterns ofTGF-beta 1 expression following renal transplantation.
6.3.2 NAG expression in urine
No patients had microbiological evidence of urosepsis at the time of sample
collection. NAG excretion varied considerably between patients. Values for the CAN
and control groups were not significantly different (Figure 19). There was no
correlation between NAG excretion and GFR (Figure 20). In the CAN group, the
change in NAG excretion over 6 months in the control and intervention groups was
not significantly different (Figure 21), nor was there a significant difference between
patients grouped according to the rate of decline in their transplant function over the
same time period.
These cross-sectional and longitudinal data suggest that urine NAG excretion is not a
specific marker for CAN in renal allograft recipients, nor is it a useful marker of an
early response (as measured by change in GFR) to immunosuppression conversion
therapy in such patients.
Modified studies that examine combinations of candidate non-invasive markers of
incipient CAN may be contemplated in the future. Control groups need to be
rigorously defined. As stated in Section 5.3.1, the addition of histopathological
criteria to those specified in our study would reduce the likelihood of including
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patients with subclinical CAN as controls. Proteomic analyses may help to identify a
family of discriminatory urine markers for inclusion in future non-invasive graft
surveillance programmes. The term proteome refers to all the proteins expressed by
a genome, and thus proteomics involves the identification of body proteins and the
determination of their role in physiological and pathological functions. The -30,000
genes defined by the Human Genome Project produce 300,000 to 1 million proteins
when alternate splicing and post-translational modifications are taken into account.
Whereas an individual's DNA genome remains essentially unchanged through life,
the protein content of body cells changes continually as genes are turned on and off
in response to variation in the cell environment. Proteins cannot be amplified like
DNA, therefore less abundant sequences are more difficult to detect. In addition,
enzymes, heat, light and aggressive mixing may alter the secondary and tertiary
structure of proteins during the analytical process. Several major technologies are
used in protein analysis, including 2-D polyacrylamide gel electrophoresis (2-D
PAGE) for protein separation, mass spectrometry (combined with ionisation
methods) for protein identification, post-translational analysis (enzymatic and
antibody-binding methods to detect protein phosphorylation and glycosylation), and
bioinformatics. Protein microarray technology has recently been developed and can
be used for protein expression profiling. Many types of substances can be bound to
protein microarrays including antibodies, receptors, ligands, nucleic acids and
carbohydrates. Some surfaces have broad specificity while others are highly specific
and bind only a few proteins from a complex sample. After the capture step, the array
can be washed to reduce non-specific binding. When subjected to short bursts of
laser light, the retained proteins become uncoupled from the array surface and can
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then be analysed by laser ionisation time-of-flight mass spectrometry. One potential
problem with proteomics in the context of early detection of CAN is that different
urinary proteins (of glomerular or tubular source) may be expressed at different
stages in the progression of the disease. Large, prospective longitudinal studies will
be required.
6.3.3 GFR prediction formulae and measurement of serum cystatin C
GFR prediction formulae
The median value of the corrected 99mTcDTPA-GFR measurements in the
population of renal transplant recipients with CAN was 28 (range 15-55)
ml/min/1.73m2. Bias and scatter values for the various GFR prediction formulae are
shown in Table 7.
Table 7. Bias and scatter values for the GFR prediction formulae
Formula MDRD Jelliffe C & G Walser Nankivell Bokenkamp
Required data1 A,G,R,C, A,G,C A,G,C, A,G,C, G,Cr,U,W, Cystatin C
U,Alb W W,H H
Bias (ml/min)2 -1 +3 +7 -2 +7 +11
Scatter (ml/min)3 3 5 6 4 10 11
1 A - age, G - gender, R - race, Cr - serum creatinine, U - serum urea, Alb - serum
albumin, W - weight, H - height
2 median difference between calculated GFR and reference (99mTcDTPA-GFR)







The MDRD formula gave the lowest bias and scatter (Figure 22). One patient was
clearly an outlier, with an MDRD-GFR of only 17 ml/min/ 1.73m2, compared to 35
ml/min/1.73m2 measured by 99mTcDTPA clearance. The mean of his measured urea
and creatinine clearances (from a 24-hour urine collection) was 34 ml/min/1.73m ,
suggesting that the MDRD-GFR estimate was inaccurate. The patient was a body¬
builder with an unusually large muscle mass.
Serum cystatin C and Cys-GFR
There was a strong correlation between 99mTcDTPA-GFR and the reciprocals of
serum cystatin C and serum creatinine at 0 and 6 months (1/cystatin C vs
99mTcDTPA-GFR, r = 0.83 and 0.87, p<0.001; 1/creatinine v.v 99mTcDTPA-GFR,
r = 0.78 and 0.77, p<0.001; 1/creatinine vs 1/cystatin C, r = 0.86 and 0.87, p<0.001).
Figure 23 illustrates graphically the relationship between 1/cystatin C and
99mTcDTPA-GFR values at the start of the study. There were two clear outliers, but
repeat measurements at 6 months placed them closer to the regression line.
Interestingly, the outlier for whom 1/cystatin C produced an underestimate of GFR
was a body builder. He admitted to taking anabolic steroids, which may be
significant in view of the recent findings of Risch and coworkers that glucocorticoids
may increase serum cystatin C values (Risch et al 2001).
The calculated Cys-GFR values tended to exceed the corresponding 99mTcDTPA-
GFR values, with a positive bias (median difference in values) of 10.9
ml/min/1.73m2 and scatter (median absolute difference in values) of 11.1
ml/min/1.73m2 (Figure 24). The Bokenkamp formula for Cys-GFR is based on serum
cystatin C values that were obtained using a PETIA assay. Erlandsen et al reported a


























(Erlandsen et al 1999). They have produced a regression equation to express the
relationship of cystatin C values obtained using the two assays. We 'standardised'
our PENIA-derived values using this equation but still found a large positive bias of
approximately 7.5 ml/min/1.73m2 for the Bokenkamp formula.
In summary, it can be concluded from the above studies of adult renal transplant
recipients with chronic renal allograft dysfunction of wide-ranging severity that (1)
the MDRD-GFR formula provides a valid estimate of renal clearance, and (2) serum
cystatin C correlates more strongly with a 'gold standard' of GFR measurement
(99mTcDTPA-GFR) than does serum creatinine. The MDRD-GFR formula is now
available on a number of websites (including the Renal Association website at
http://www.renal.org/Resources/MDRD-GFRcalculator.htm) and there have been
discussions locally to facilitate the addition of MDRD-GFR to the laboratory
reporting service. The most important advantage of serum cystatin C over serum
creatinine is its greater sensitivity for detecting mild impairment of renal function.
An earlier awareness of diminishing renal clearance increases the opportunity for
effective therapeutic intervention. The PENIA assay is now fully automated and this




Treatment of patients with established CAN - a
prospective study of immunosuppression
conversion
It has been suggested by several authors that the promising results achieved in pilot
studies of immunosuppression conversion for CAN should be confirmed by larger,
more rigorous studies that are prospective, randomised and controlled.
Randomisation adds validity to a study by eliminating selection bias. The inclusion
of a control group of patients whose immunosuppression remains unchanged and the
use ofgold-standard isotope techniques rather than serum creatinine to estimate renal
clearance are also of crucial importance. The pattern of functional decline in CAN is
non-linear, such that a phase of stability could be attributed falsely to a coincident
change in treatment (Kasiske et al 1991). There may also be a confounding effect of
study participation. For example, study participants may be managed by a relatively
small number of senior research staff and receive more regular review than non-
participants. For these reasons, it is clear that study findings are invalid unless
control group data are available for comparison.
A reference method ofmeasuring GFR is likely to provide much clearer information
about renal function than serum creatinine, which can be misleading because of its
poor sensitivity (as discussed in Chapter 3). In addition, non-renal factors (diet,
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hydration status, patient medication and others) are known to have an effect on
serum creatinine and the assays that are used in its measurement.
In response to the early reported experience with immunosuppression conversion for
CAN and some encouraging results from a small study conducted in Liverpool, a
team of senior surgeons and physicians from three regional transplant centres
(Liverpool, Manchester and Leeds) met to formulate a larger, collaborative study.
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7.1 Subjects and methods
Details of the study methodology are presented here in accordance with the revised
CONSORT guidelines (Moher et al 2001).
7.1.1 Participating centres
The participating centres were St James's University Hospital (SJUH) in Leeds, the
Royal Liverpool and Broadgreen University Hospitals (RLBUH) and Bradford St
Luke's Hospital (BSLH). Potential study participants from the BSLH were
identified, investigated and monitored by the research team at SJUH.
7.1.2 Investigators
The team at SJUH comprised a medical research fellow (Dr J Stoves), a research
nurse (Sister H Ingles/ Mr J Carr) and a supervising senior consultant (Dr CG
Newstead) with a specific interest in transplant medicine. The team in Liverpool
included a surgical research registrar (Dr M Paraoan), a study coordinator (Mr G
Owens) and a consultant transplant surgeon (Mr AQ Hammad). Laboratory work
was performed in the Department of Renal Research at Manchester Royal Infirmary
by Dr J Stoves under the auspices of Dr PEC Brenchley and his team of scientists
(notably Dr S Williams, Dr B Coupes and Mr ID Read).
7.1.3 Planning of study and ethical approval
The study was planned in accordance with the Declaration of Helsinki (World
Medical Association. Declaration of Helsinki 2001), Good Clinical Practice for
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Trials on Medical Products in the European Union and the CONSORT guidelines
(Moher et al 2001). Local Research Ethics Committee (LREC) approval of the study
was obtained in both Liverpool (1998) and Leeds (1999) prior to its commencement.
7.1.4 Patient identification
The electronic records of renal transplant recipients receiving follow-up care in the
participating units were reviewed systematically to identify patients with progressive
allograft dysfunction, defined by a downward sloping 'reciprocal of serum creatinine
versus time' (ROCT) plot over a minimum period of 6 months. Several reviews were
performed during the course of the study. The suitability of patients for study entry
was assessed in the clinic.
7.1.5 Entry criteria
The main inclusion and exclusion criteria for the study are summarised below:
Inclusion criteria
1) Above the age of 18 years
2) Receiving CsA-based immunosuppression
3) At least 6 months post-renal transplant, with no episodes of acute rejection during
the preceding 3 months
4) Deteriorating renal function, in particular a sustained increase in serum creatinine
for a minimum of 6 months




1) Previous treatment with tacrolimus, MMF or RPM
2) HIV, HBV or HCV infection
3) Serum creatinine of above 400 p.mol/1
4) Pregnant or breast-feeding women
5) Female patients unwilling or unable to use approved contraception during the
study and for 6 weeks following completion of the study
6) Presence of significant, uncontrolled concurrent infection
7) Participation in another clinical trial during the previous month.
7.1.6 Preliminary patient investigations
Patients who fulfilled the first four inclusion criteria and were otherwise eligible for
participation in the study were referred for renal transplant ultrasonography and a
colour flow Doppler assessment of the renal transplant vessels. The lead investigator
proceeded to obtain a transplant biopsy specimen when the above investigations
showed no abnormalities. Biopsy material was examined by a nominated
histopathologist and classified according to the Banff 97 criteria (Racusen et al
1999).
7.1.7 Discussion and consent
Patients with biopsy-proven CAN patients were provided with a leaflet that
contained important information regarding the background to the study, the rationale
for intervention, the timetable of the study, profiles of the study medications
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(tacrolimus and MMF) and issues of patient consent and confidentiality of study
data.
7.1.8 Randomisation
Patients who consented to being included in the study were allocated randomly to
one of the three treatment arms using a computer-generated sequence that was
obtained from an independent source. Information regarding the randomised
treatment was concealed in sequentially numbered sealed, opaque envelopes. These
were opened in the presence of the patient (by JS at SJUH/ BSLH and GO at
RLBUH) immediately after obtaining informed, written consent for participation in
the study. All patients were allocated a unique numerical identification code based on
the study centre to which they were attached and their place in the chronological
order of randomisation within that centre. If a patient was removed from the study
prematurely, his or her number was not reassigned to another patient. Both patient
and physician were necessarily aware of the randomised treatment in all cases, but
members of staff in the various clinical laboratories (including Medical Physics and
Chemical Pathology) were blinded to this information. Prescriptions for new
therapies were provided initially through the hospital pharmacy.
7.1.9 Treatment options
The randomised treatments were as follows: (A) MMF and reduced dose CsA; (B)
tacrolimus in place of CsA; (C) 'no change' (continuation of a CsA-based
immunosuppressive regimen). The protocol for each is summarised below.
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A. MMF and reduced dose ofCsA
1) MMF 500 mg bd added to regimen and azathioprine discontinued at enrolment
2) MMF increased to 750 mg bd and CsA dose reduced by 25% at the beginning of
week 2
3) MMF increased to 750 mg bd and CsA dose adjusted to achieve a trough blood
level of 75-100 ng/ml (monoclonal assay, Abbott Diagnostics, Delkenheim,
Germany) at the beginning ofweek 3
4) In case of bone marrow suppression, MMF reduced as per the following regimen:
Peripheral blood white cell count 3-4 x 109/ml - reduce dose to 750 mg bd
Peripheral blood white cell count 2-3 x 109/ml - reduce dose to 500 mg bd
Peripheral blood white cell count < 2 x 109/ml - discontinue MMF for 10 days
and restart at 500 mg bd ifwhite cell count > 4 x 109/ml
Neutropenia for more than 2 weeks - withdraw from study
B. Tacrolimus in place ofCsA
1) CsA discontinued at enrolment and tacrolimus started at a dose of 0.1 mg/kg/day
12 hours after the last dose of CsA, or 24 hours ifCsA trough blood level > 300
ng/ml
2) Target tacrolimus trough blood level of 5-10 ng/ml (Tacro assay, Abbott
Diagnostics, Delkenheim, Germany) during the study period
C. Control group
No change to treatment regimen, target CsA trough blood levels maintained as per
unit protocol during the study period
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Continuation of a CsA-based regimen has been regarded hitherto as a 'best practice'
strategy for long-term immunosuppression. It was considered likely that any
treatment disadvantage for the control group over a period of 6 months (the length of
the study period) would be small.
7.1.10 Dosing and administration of additional medication
All treatments that were commenced during the study period were recorded,
including dose and indication. ACE inhibitor and HMG-CoA reductase inhibitor
(statin) medications were not added to patient treatment regimens (as per study
protocol).
7.1.11 Safety assessment
Following enrolment, all patients were evaluated for adverse events. An adverse
event was defined as any untoward medical occurrence (i.e. including events that did
not necessarily have a causal relationship to trial medications). A clinical
examination and laboratory safety tests were performed at each clinic visit.
7.1.12 Baseline investigations
Baseline investigations comprised the following: height, weight, blood pressure,
GFR (measured by clearance of 99mTcDTPA), full blood count (FBC), renal
biochemistry, glucose, HbAlc (glycosylated haemoglobin), fasting lipids (total
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides), CsA trough blood
level, urine protein creatinine index (PCI) and MSSU for microscopy, culture and
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sensitivity. These investigations were repeated at varying intervals during the 6
months study period.
7.1.13 99mTcDTPA-GFR measurement
This comprised upper limb intravenous injection of a small volume of isotonic
solution containing 99m technetium of known radioactivity bound to DTPA and
blood sampling from the contralateral limb at 2, 3 and 4 hours post-injection. The
degree of residual radioactive signal present in the samples was plotted on a decay
curve, from which a crude GFR was calculated and subsequently adjusted for body
surface area using the Dubois formula (Dubois et al 1916). All GFR measurements
were performed in the mid-morning to early afternoon period.
7.1.14 Subjective assessment of quality of life and medication side-
effects using a validated questionnaire
Patients were asked to complete a validated, gender-specific questionnaire (Modified
Transplant Symposium Occurrence and Symptom Distress Scale, Moons et al 1998)
at the beginning and the end of the study after providing informed consent. The
questionnaire comprised more than 40 questions, many of which focused on the
recognised side effects of immunosuppressive therapy that occur in transplant
recipients. Patients were able to grade both the frequency of occurrence and severity
of specific symptoms. Intraindividual differences in questionnaire scores (obtained
by subtraction of the final score from the initial score) are to be compared across
treatment groups using Mann Whitney. Completion of the statistical analysis is the
responsibility of the team in Liverpool.
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7.1.15 Study schedule
Patients were given a study schedule containing dates for subsequent clinic visits. A
letter confirming study entry was sent to the general practitioner. Patients were
reviewed weekly for the first month, fortnightly for the second month and monthly
thereafter. A second 99mTcDTPA-GFR measurement was performed at the end of
the 6 months study period. Each patient's immunosuppressive regimen was reviewed
following completion of the study.
7.1.16 Study outcome measures
Primary study outcome measure
The primary outcome measure was change in renal function. This was assessed by
comparing 99mTcDTPA-GFR values at the start of the study and at its conclusion 6
months later, and also the slope of ROCT plots before and after treatment
intervention (using creatinine data from 12 months pre-study to 12 months post-study
entry).
Secondary study outcome measures
Hypertension and hypercholesterolemia, two important side effects of
immunosuppressive therapy, were selected as the secondary study outcome
measures. Change in urine protein creatinine index (PCI, a measure of the degree of
proteinuria) was also assessed.
7.1.17 Power calculation
A power calculation was performed to determine the number of patients that would
be required for clinically relevant differences in outcome between treatment groups
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to reach statistical significance. There are obvious problems with performing power
calculations in this setting. Firstly, there is a variable rate of functional decline in
some patients with CAN, such that slowing of disease progression may be
independent of the therapeutic intervention. Secondly, the likely effect on allograft
function of immunosuppression conversion is difficult to estimate because of
insufficient preliminary data. Assuming a standard deviation (SD) of 4
ml/min/1.73m2 per year for the annual reduction in GFR in patients with CAN, a
study population of 48 patients would be required for a difference of 3
ml/min/1.73m2 per year in the rate of deterioration between treatment groups to be
statistically significant (p<0.05, power 80%).
7.1.18 Interim analysis
A statistician performed an interim analysis of the data after 36 patients had
completed the study (three-quarters of the required number). The statistician was
otherwise uninvolved with the study. There were two main reasons for not
performing the analysis sooner (i.e. a bias towards collective ethics rather than
individual ethics). Firstly, the differences in outcome between the three treatment
groups were not expected to be large. Secondly, the study was of short duration and
it was felt that the initiation of a more effective treatment (if this were to be proven)
for a chronic pathology could be deferred without major consequences for individual
patients.
The analysis was reviewed by senior clinicians who had been involved in the




We performed an 'on-study' analysis of patient data. The difference in slope of the
pre- and post-intervention ROCT plots was calculated for each patient and an
intergroup comparison of values was made using a Kruskal-Wallis test. It was not
assumed that pre-study (-12/12-0) and post-study (0 - 6/12) slopes would have a
common intercept at time zero. Intergroup comparisons of changes in GFR,
cholesterol, triglycerides, systolic and diastolic blood pressure (SBP, DBP) between
the start and the finish of the study were also made using a Kruskal-Wallis test.
Analysis of covariance (ANCOVA) was performed to assess the relevance of the
pre-study GFR to therapeutic response.
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7.2 Results
The first study patient was enrolled in July 1999. It was decided in March 2001 that
no patients would be recruited into the study after December 2001 because of a
paucity of new cases in the three participating centres. The study was completed (last
patient out) in June 2002. Forty-two patients entered the study, less than the target
number derived from the power calculation. This was because of a slow take-on rate
towards the end of the recruitment period.
Baseline data for the three study groups are summarised in Table 8. It is apparent that
the groups were broadly similar. Age at transplantation and time post-transplant were
higher in the MMF/ reduced dose CsA group and there was a larger proportion of
female patients. Five patients were recipients of living donor grafts, two in the
tacrolimus group and three in the control group. Four patients had pre-transplant
diabetes mellitus, one in each of the intervention groups and two in the control
group. There was no significant difference between groups in the distribution of pre-
study ROCT linear regression slopes. HMG-CoA reductase inhibitors and ACE
inhibitors were not added to any of the treatment regimens during the study period.
A patient flow chart for the study participants is shown in Figure 25. Two patients
started dialysis treatment during the 6 months study period, one in each of the
intervention groups. In both cases the initial GFR was below 20 ml/min/1.73m2 and
there was evidence of a rapid pre-study decline in graft function. An end-of-study
GFR of 5 ml/min/1.73m2 was assumed for both patients in the main GFR analysis.
Similarly, two patients who failed to attend for an end-of-study GFR measurement
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Table 8. Patient demographics by study group
MMF/ CsA FK506 in place Continuation
dose reduction ofCsA of CsA
Age at transplant (years) 37 (27-47)1 26 (22-32) 30.5 (26.8-41.5)
Time since transplant (years) 8.7 (6.3-9) 7(5-10) 4.6(4.1-7.2)
Gender (male/ female) 6/7 10/3 12/4
Ethnicity (White/ Asian) 12/1 13/0 16/0
Donor age (years) 44 (22-50) 39(19.5-43.5) 46.5 (42.8-53)























CsA trough level (CO) 146 (116-185) 142 (118-170) 160 (135-225)
Serum creatinine (umol/1) 206(188-307) 216(174-296) 235(171-328)
99mTc-DTPA GFR
(ml/min/1.73m2)


































P = prednisolone, C = cyclosporin, A = azathioprine
1 Median value and interquartile range
2
Not performed in one of the three centres
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(a control group patient and a patient who appeared to have responded well to a
MMF/ reduced dose CsA regimen according to serum creatinine values) were not
included in the GFR analysis. GFR was not measured in another control group
patient because of her needle phobia.
One patient was intolerant ofMMF and withdrew from the study after a few days of
treatment. His data were disregarded as we wished to examine the 'on-study'
effectiveness of treatments rather than analyse outcomes on an 'intention-to-treat'
basis.
CsA dose was reduced by a median of 24% (interquartile range (IQR) 14%-27%) in
the group receiving MMF, giving a median end-of-study CsA trough blood level of
99 (IQR 90-113) ng/ml. The median maintenance dose ofMMF was 1.5 (IQR 1.5-2)
g/day. The median end-of-study tacrolimus trough blood level in the group receiving
tacrolimus was 7 (IQR 5-9) ng/ml. The median end-of-study CsA trough blood level
for patients in the control group was 163 (IQR 145-215) ng/ml.
ROCT plots were constructed for each patient, taking creatinine data from 12 months
before to 12 months after study entry. . During the 'run-in' period, serum creatinine
was measured when patients attended for routine clinical review. The median
number of creatinine values per patient over the 'run-in' period was 10 (interquartile
range 7 to 12). A comparison of change in ROCT slope revealed a significant
treatment advantage for patients in group A (Kruskal Wallis test, p < 0.05). Dotplots
for post-treatment slope and change in slope are shown in Figure 26.
A separate analysis comparing the pre-study ROCT slope to the slope for the 3-12
months post-study period (i.e. excluding data collected in the first 2 months of the
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study, by which time any beneficial effect of CsA dose reduction on renal transplant
haemodynamics was likely to have occurred) also showed a difference between
treatment groups, although this was not statistically significant (Figure 27, p = 0.08).
Figure 28 is an identity plot to show the post-treatment ROCT slopes for the time
periods 0-6 months and 3-12 months in the group of patients receiving MMF/
reduced dose CsA and standard dose CsA controls. Slopes were similar in control
patients, whereas in the intervention group the 3-12 months slopes tended to be more
negative than the corresponding 0-6 months slopes.
The analysis of GFR data (available in 37 patients) also showed a trend towards a
treatment advantage for MMF/ reduced dose CsA (Figure 29, p = 0.05). The median
increase in GFR after 6 months of follow-up for this group was 2.5 (IQR 0.3 - 9)
ml/min/1.73m2. The corresponding values for the tacrolimus and control groups were
-0.6 (IQR -7.4 - 3.0) ml/min/1.73m2 and -0.7 (IQR -1.4 —0.1) ml/min/1.73m2
respectively. Figure 30 shows the correlation between change in GFR and the slope
of the ROCT plot between 0 and 6 months (r = 0.61, p < 0.001). An ANCOVA
model including GFR at the start of the study (GFR0) as a covariate showed that
GFR0 was a significant predictor of response to treatment (p < 0.05). To explore this
further, patients with poor initial transplant function (GFR < 20 ml/min/1.73m2) were
excluded from a repeat analysis. This showed a similar but more exaggerated trend
toward a treatment advantage for MMF/ reduced dose CsA (Figure 31, n = 27, p <
0.05). The median increase in GFR in the MMF/ reduced CsA group was 3.3
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Table 9. Change in blood pressure, serum lipids and urinary protein excretion
(pre-study minus post-study values) in the three treatment groups
0.3 (-0.7-0.9) 0.9(0.1-1.4) 0.4 (-0.1 - 0.8)
Variable [number with data] MMF/ CsA Tacrolimus in Continuation
dose reduction place ofCsA of CsA
Systolic blood pressure 6 (-8 — 22)1 10 (-10 — 22) 5 (-10 — 20)
(mmHg) [41]




Low density lipoprotein (LDL) -0.4 (-1 — 0.4) 0.6 (0.1 — 1) 0.1 (-0.2 — 0.2)
cholesterol (mmol/1) [27]
High density lipoprotein (HDL) 0 (-0.1 — 0.3) 0.1 (0.0 - 0.2) 0 (-0.2 — 0.1)
cholesterol (mmol/1) [41]
Triglycerides (mmol/1) [41] 0.1 (-0.3 - 0.2) 0 (-0.3 - 0.8) 0.2 (-0.3 - 0.5)
Urine protein creatinine index 8 (-36 - 66) -48 (-200 - 39) -4 (-70 — 62)
(PCI) [27]
1 median (interquartile range)
The changes in fasting lipid profile, arterial blood pressure and proteinuria during the
course of the study are summarised in Table 9. Blood pressure reduction was more
substantial in the intervention groups but this did not reach statistical significance.
There was also a non-significant trend towards an improvement in the serum lipid
profile of patients receiving tacrolimus as compared to controls. There were no
significant differences between treatment groups at the start and at the end of the
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study period in terms of the number of prescribed antihypertensive agents. The
change in urine PCI during the 6 months study period in the three treatment groups
was not significantly different.
In the MMF/ reduced dose CsA group, gastro-intestinal disturbance occurred in six
cases. This generally improved with MMF dose reduction. Two patients experienced
insomnia. One patient required treatment for a recurring external ear infection. MMF
dose was reduced in three patients because of progressive anaemia. One patient in
the tacrolimus group developed progressive hair loss and her treatment was
discontinued shortly after study completion. Another patient receiving tacrolimus
required treatment for acne. Of the patients in the control group, one required
surgical drainage of a perianal abscess, one developed acute gout and another
required treatment for a urinary tract infection. None of the study patients developed
acute rejection or de novo diabetes mellitus.
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4.3 Discussion
This is the second prospective randomised controlled trial of immunosuppression
conversion for CsA-treated renal transplant recipients with established CAN. The
Creeping Creatinine Study examined the effect of introducing MMF followed by
complete withdrawal of CsA and is unique in having a control arm (Dudley 2002).
Renal function stabilised in 58% of patients receiving MMF in place of CsA (n = 73)
as compared to 28% of controls (n - 70) during a follow-up period of 34 weeks.
Three deaths occurred in the MMF group. There was no difference between groups
in the incidence of acute rejection.
Our study provides evidence of a treatment advantage for MMF/ reduced dose CsA
as compared to substitution of tacrolimus for CsA and standard dose CsA in patients
with established CAN, at least in the short term. A reference method of GFR
measurement (99mTcDTPA-GFR) was used to monitor change in transplant function
in addition to more frequent serum creatinine measurements. 99mTcDTPA-GFR was
performed only twice (at the start of the study and 6 months later). ROCT plots gave
more information about pre-study patterns of functional attrition and longer-term
outcome (up to 12 months after study entry). Analyses of GFR and creatinine data
gave similar results. It would have been preferable for the number of study
participants to at least equal the power calculation estimate but this could not be
achieved within the time limits of the study.
The apparent success of the above regimens could be explained simply in terms of
the known effect ofCsA on renal haemodynamics (Curtis et al 1986) and pro-fibrotic
cytokine expression (Ghiggeri et al 1994; Shihab et al 1996). MMF is effective in
reversing some of the histopathological features of CAN in both renal and aortic
allograft models of chronic rejection in the rat (Raisenen-Sokolowski et al 1994;
Azuma et al 1995) and therapeutic concentrations of the drug inhibit fibroblast
growth in cell culture studies (Zeier et al 2001). There is also some evidence that the
use of MMF in place of AZA produces clinical benefit in terms of a reduced
incidence of chronic renal allograft failure (Ojo et al 2000). Our comparison of pre-
study and 3-12 months post-study slopes (attempting to separate the effects ofMMF
and CsA dose reduction, the latter producing an acute alteration in renal transplant
haemodynamics) suggests that MMF may itself favourably affect long term outcome
in CAN but this needs to be confirmed by a more extended period of follow-up of
study participants.
It may be that the reported side effects of MMF therapy in the study participants
were related to the degree of systemic exposure to the drug. Measurement of
mycophenolic acid (MPA, the active metabolite of MMF) blood levels may have
been informative in this regard.
The importance of intervening at a relatively early stage in the development ofCAN
is highlighted by two separate findings of this study. Firstly, baseline GFR (GFR0)
was found to be a significant predictor of outcome in an analysis of covariance
(ANCOVA) model with GFR0 as the covariate. Secondly, an analysis of change in
GFR that excluded patients with a GFR of less than 20 ml/min/1,73mz revealed a
more definite difference in outcome between the treatment groups. These findings
emphasise the need for prompt detection of CAN, either by protocol biopsy or the
use ofmore sensitive and specific tests ofblood and urine (see Chapter 6).
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The rate of change of GFR was reduced in some patients receiving tacrolimus, but
the treatment response in the tacrolimus-treated group as a whole was not superior to
controls. The characteristics of patients who appeared to respond well were not
different to those of others in the group. There was a non-significant trend towards an
improvement in the serum lipid profile of tacrolimus-treated patients as compared to
controls.
In summary, this randomised, controlled comparative study of immunosuppression
regimens in patients with established chronic allograft nephropathy provides
evidence to support the use ofMMF and low dose CsA in preference to a standard
dose CsA-based regimen. More substantial reductions in CsA dose may produce an
even better outcome, as this component of the regimen appears to have the greatest
impact on graft function, at least in the short term. However, the increased risk of
acute graft dysfunction associated with total CsA withdrawal needs to be considered
(Stoves et al 2002a). Further studies to compare MMF-based regimens with newer
immunosuppressive agents such as rapamycin may help to determine an optimal
regimen for the prevention and treatment of CAN. Timely intervention depends on
early detection ofCAN. This is probably best achieved by protocol transplant biopsy
or the development of valid non-invasive tests of renal allograft injury. Control of





Chronic allograft nephropathy (CAN) remains a major cause of late renal transplant
loss despite substantial reductions in the incidence of early acute rejection. Renal
transplant recipients with allograft failure secondary to CAN account for roughly 3%
of all entrants to chronic dialysis programmes in the UK, increasing the demand
placed on this limited resource. Allograft failure also has a considerable impact on
patients awaiting call-up for transplantation, for example as many as 1 in every 6
patients transplanted in the UK in the year 2000 had previously received a renal
transplant. It is therefore very important that the clinical management of renal
transplant recipients (RTRs) should include anticipation, prevention, early detection
and optimal treatment of CAN. The component studies of my thesis have addressed
specific areas within each of these main divisions.
The notion of a screening programme for potential RTRs to reduce the prevalence of
CAN through identification of those 'at risk' is a credible one. However, the
inclusion in such a programme of genetic profiling to predict post-transplant TGF-
beta 1 expression and measurement of lymphocyte sensitivity to CsA in vitro is not
supported by the study data. Modified studies that examine larger populations and
combinations of screening tests may be contemplated in the future. Control groups
need to be rigorously defined. The addition of histopathological criteria to those
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specified in our study would reduce the likelihood of including patients with
subclinical CAN, although most UK transplant centres do not routinely perform
transplant biopsies in patients whose graft function is stable.
It would also appear that the measurement of candidate urine markers for incipient
CAN (TGF-beta 1 and the lysosomal enzyme NAG) is of little predictive or
diagnostic value. Proteomic analyses may help to identify a family of discriminatory
urine markers for inclusion in future non-invasive graft surveillance programmes.
One potential problem with this approach is that different urinary proteins (of
glomerular or tubular source) may be detected at different stages in the development
and progression ofCAN. Large, prospective longitudinal studies will be required.
The studies relating to measurement of serum cystatin C (a more sensitive marker of
small reductions in GFR than serum creatinine) and calculation of GFR using the
Levey (MDRD) prediction formula indicate that both are useful in the detection
and/or quantification of early renal allograft dysfunction. An earlier awareness of
diminishing renal clearance would increase the opportunity for effective therapeutic
intervention.
We have also produced evidence that a more accurate quantification of CsA
exposure may be important in reducing both the incidence of acute transplant
rejection during the immediate post-transplant period (a well documented risk factor
for the development of CAN) and the rate of chronic disease progression in
established CAN. A large intra-individual variation in CsA exposure may indicate
poor adherence to treatment regimens rather than variation in drug bioavailability. It
is of course possible that calcineurin inhibitor therapy (in particular CsA) will not be
used for maintenance immunosuppression in the future, as there are now alternative
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agents such as rapamycin that are effective, cause less nephrotoxicity and have a
more favourable pharmokinetic profile (in particular a longer plasma elimination
half-life).
In the study of immunosuppression conversion for RTRs with established CAN, a
comparison of reciprocal of creatinine vs time (ROCT) slopes before and after
intervention revealed a treatment advantage for patients whose immunosuppression
was changed to MMF/ reduced dose CsA. Similar results were obtained in the GFR
analysis. Exclusion of patients with an initial GFR < 20 ml/min/1.73m2 from the
analysis gave a result that was statistically and clinically more striking, indicating
that immunosuppression conversion should be considered at an early stage in the
development of CAN. The number of study participants was suboptimal, mainly
because of slow recruitment in some of the participating centres. A more extended
period of follow-up would have provided information about the longer-term safety
and effectiveness ofMMF in combination with reduced dose CsA for the treatment
of CAN. Future research should include a comparison of MMF with other
immunosuppressive therapies such as rapamycin, perhaps with more substantial
concomitant reductions in CsA dose than were attempted in this study.
The research findings that are presented in this thesis have been disseminated at
national and international meetings and in peer-reviewed journals (Stoves et al 2000,
2001a/b, 2002b/c/d/e, 2003, www.leeds.ac.uk/ykrf). Others may be encouraged to
seek confirmation of our findings in larger prospective studies.
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